Ghid practic de utilizare a medicamentelor în Oftalmologie

Bibliografie

Capitolul 1

  1.  Dave VS, Bhansali SG. Pharmacokinetics and Pharmacodynamics of Ocular Drugs. Springer, 2016. 
  2. Shen J, Lu GW, Hughes P. Targeted Ocular Drug Delivery. Springer, 2018.
  3.  Agrahari V et al. Comprehensive Insight on Ocular Pharmacokinetics. Controlled Release Society, 2016. 
  4. Velpandian T. Pharmacology of Ocular Therapeutics. Adis, 2016. 
  5. Urtti A. Challenges in Ocular Pharmacokinetics and Drug Delivery. Elsevier, 2006. 
  6. Gilger BC. Ocular Pharmacology and Toxicology. Humana Press, 2014. 
  7. Fulga, I. Farmacologie. Ediția a 2-a revizuită și adaugită. 2nd ed. București: Editura Medicală, 2024
  8. Goodman and Gilman,s the Pharmacological Basis of Therapeutics, 14th Edition, Ed.
  9. Mcgraw Hill Education & Medic, 2022.
  10. John W. Shell, Pharmacokinetics of topically applied ophthalmic drugs, Survey ofOphthalmology, Volume 26, Issue 4, 1982, Pages 207-218, ISSN 0039-6257,
  11. Agrahari Vet al A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res. 2016 Dec;6(6):735-754. doi: 10.1007/s13346-016-0339-2.
  12. Charles NJ McGhee: Ocular Therapeutics, An overview of topical ophthalmic drugs and the therapeutics of ocular infection, 2004
  13. Katzung’s Basic & Clinical Pharmacology, 16 th Edition, Ed. Todd W. Vanderah.McGraw-Hill, 2024
  14. American Academy of Ophthalmology. Basic and Clinical Science Course. 2019
  15. Velpandian T. Drug Transport Across Blood-Ocular Barriers. Springer, 2016.
  16. Beauchamp D, Labrecque G. Chronobiology and Chronotoxicology of Antibiotics. Elsevier, 2007. 
  17. Agrahari V et al. Anterior and Posterior Chamber Pharmacokinetics. Controlled Release Society, 2016.
  18. Shen J et al. Pharmacokinetics in Ophthalmology. Springer, 2018.
  19. A A Mangoni , S H D Jackson. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. British Journal of Clinical Pharmacology, Volume 57, Issue 1 p. 6-14
  20. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. The AAPS J ,2010; 12(3):348–60 
  21. Edelhauser HF, Rowe-Rendleman CL, Robinson MR, Dawson DG, Chader GJ, Grossniklaus HE, et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.Investigative ophthalmology & visual science. 2010; 51(11):5403–20. [PubMed: 20980702] 
  22. Charles NJ McGhee. An overview of topical ophthalmic drugs and the therapeutics of ocular infection. Ocular Therapeutics guide. 
  23. Vibhuti Agrahari, Abhirup Mandal, Vivek Agrahari et. Al. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res. 2016 December; 6(6): 735–754.doi:10.1007/s13346-016-0339-2.
  24. Charles NJ McGhee. An overview of topical ophthalmic drugs and the therapeutics of ocular infection. Ocular Therapeutics guide.  
  25. Ingrida Januleviciene, Lina Siaudvytyte, Ruta Barsauskaite. Ophthalmic Drug Delivery in Glaucoma—A Review. Pharmaceutics. 2012 Mar 21;4(1):243–251.
  26. Vibhuti Agrahari, Abhirup Mandal, Vivek Agrahari et. Al. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res. 2016 December; 6(6): 735–754.doi:10.1007/s13346-016-0339-2. 
  27. Kymionis GD, Bouzoukis DI, Diakonis VF, Siganos C. Treatment of chronic dry eye: focus on cyclosporine. Clinical ophthalmology. 2008; 2(4):829–36. [PubMed: 19668437] 
  28. Mathews D, Mathews J, Jones NP. Low-dose cyclosporine treatment for sight-threatening uveitis: efficacy,toxicity, and tolerance. Indian journal of ophthalmology. 2010; 58(1):55–8. [PubMed: 20029146] 
  29. Esen Karamursel Akpek, Jason Vittitow,Rozemarijn S. Verhoeven et al. Ocular Surface Distribution and Pharmacokinetics of a Novel Ophthalmic 1% Azithromycin Formulation.Journal of ocular pharmacology and therapeutics. Volume 25, Number 5, 2009 
  30. Manoj Kumar Mishra, Vaidehi Kumari, R. K. Singh. A Comparative Study between Oral Azithromycin and Doxycycline for the Treatment of Meibomian Gland Dysfunction, International Journal of Pharmaceutical and Clinical Research 2022; 14(8); 222-229 
  31. Gauti Johannesson, Maria D Moya- Ortega et al. Kinetics of γ-cyclodextrin nanoparticle suspension eyedrops in tear flui. Acta Oftalmo. 2014 Sep;92(6): 550-6.doi: 10.1111/aos.12334. Epub 2013 Dec 24.
  32. Kapanigowda UG, Nagaraja SH, Ramaiah B. Improved intraocular bioavailability of ganciclovir by mucoadhesive polymer based ocular microspheres: J of Faculty of Pharmacy, Tehran University of Medical Sciences. 2015; 23(1):49. 
  33. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007; 114(5):855–9. 

Capitolul 2

  1. O'Farrill N, Abi Karam M, Villegas VM, et al. „New Approaches to Overcoming Antimicrobial Resistance in Endophthalmitis.” Pharmaceuticals (Basel). 2024 Mar 1;17(3):321.
  2. Ordin al Ministerului Sănătății nr. 63 din 10 ianuarie 2024 privind reglementarea metodologiei de monitorizare a prescrierii și eliberării la nivel național a medicamentelor din categoria antibiotice și antifungice de uz sistemic, publicat în Monitorul Oficial nr. 41 din 17 ianuarie 2024.
  3. Cabrera-Aguas M, Chidi-Egboka N, Kandel H, Watson SL. „Antimicrobial resistance in ocular infection: A review.” Clin Exp Ophthalmol. 2024 Apr;52(3):258-275.
  4. Behar-Cohen, Francine și Chast, François, ed. Médicaments et biothérapies en ophthalmologie. Ed. Elsevier-Masson, 2023, pp. 211-230 (cap. Antibiotyques et antifongiques).
  5. Preferred Practice Pattern: Conjunctivitis, American Academy of Ophthalmology, 2023.
  6. Mannis M, Holland E, ed. Cornea. Editia a 5-a, Elsevier, 2021 cap 40 Ophthalmia neonatorum.
  7. Oikonomakou MZ, Makri OE, Panoutsou E, et al. „Bacteriology and Antimicrobial Susceptibility Patterns of Childhood Acute Bacterial Conjunctivitis in Western Greece.” Med Hypothesis Discov Innov Ophthalmol. 2019 Winter;8(4):266-271.
  8. Chan VF, Yong AC, Azuara-Blanco A, Gordon I, et al. „A Systematic Review of Clinical Practice Guidelines for Infectious and Non-infectious Conjunctivitis.” Ophthalmic Epidemiol. 2022 Oct;29(5):473-482.
  9. Preferred Practice Pattern: Bacterial Keratitis, American Academy of Ophthalmology, 2023.
  10. Barry P, Cordoves L, Gardner S ESCRS Guidelines for Prevention and Treatment of Endophthalmitis Following Cataract Surgery, publicat de ESCRS, 2013.
  11. Grzybowski A, Brona P, Zeman L, Stewart MW. Commonly used intracameral antibiotics for endophthalmitis prophylaxis: A literature review. Surv Ophthalmol. 2021 Jan-Feb;66(1):98-108.
  12.  Sadda S, Sarraf D, Bayley Freund K et al., ed. Ryan’s Retina. ediția a 7-a. Elsevier, 2023 – cap.122 Endophthalmitis.
  13. Danielescu C, Anton N, Stanca HT, Munteanu M. „Endogenous Endophthalmitis: A Review of Case Series Published between 2011 and 2020.” J Ophthalmol. 2020 Oct 23; 2020:8869590.

Capitolul 3

  1. Prusoff WH. Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. Biochim Biophys Acta. 1959. Mar;32(1):295–6
  2. Kaufman H, Martola EL, Dohlman C. Use of 5-iodo-2'-deoxyuridine (IDU) in treatment of herpes simplex keratitis. Arch Ophthalmol. 1962. Aug;68(2):235–9
  3. Marineci CD, Chirita C, Stefanescu E, Zanfirescu A, Seremet O-A, Negres S. Medicamente antivirale. Virusuri hepatice si tratamentul hepatitelor virale
  4. Marineci CD, Chirita C, Negres S. Medicamente antivirale. Tratamentul infectiilor provocate de herpesvirusuri umane
  5. Gupta SA, Agarwal R, Shrivasta S. Textbook on Clinical Ocular Pharmacology and Therapeutics First edition, Jaypee Brothers, Medical Pub, 2019, 16-18 
  6. Zimmermann MD, Thom J., Karanjit Kooner, et al.,Textbook of Ocular Pharmacology 3rd Edition, 1997
  7. Vanpouille C., Lisco A., Margolis L. Acyclovir: A new use for an old drug. Curr. Opin. Infect. Dis. 2009; 22:583–587. doi: 10.1097/QCO.0b013e32833229b8 
  8. Watson W.A., Rhodes N.J., Echenique I.A., Angarone M.P., Scheetz M.H. Resolution of acyclovir-associated neurotoxicity with the aid of improved clearance estimates using a Bayesian approach: A case report and review of the literature. J. Clin. Pharm. Ther. 2017; 42:350–355 
  9. Jiang Y.-C., Feng H., Lin Y.-C., Guo X.-R. New strategies against drug resistance to herpes simplex virus. Int. J. Oral Sci. 2016; 8:1–6
  10. Sauerbrei A. Acyclovir resistance in herpes simplex virus type I encephalitis: A case report. J. Neurovirol. 2017; 23:638–639 
  11. Poole C.L., James S.H. Antiviral Therapies for Herpesviruses: Current Agents and New Directions. Clin. Ther. 2018; 40:1282–1298. 
  12. Wilhelmus K.R. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst. Rev. 2010;1:CD002898 
  13. Thellman N.M., Triezenberg S.J. Herpes Simplex Virus Establishment, Maintenance, and Reactivation: In Vitro Modeling of Latency. Pathogens. 2017;6: E28.
  14. Meyer C. et al. Routes for drug delivery to the eye and retina: intravitreal injections and vitrectomy, cap 10 Retinal Pharmacotherapy, 2010, Pages 67-73.
  15. Wilhelmus KR. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst Rev. 2015. Jan 9;1:CD002898. 
  16. Pavan Langston D. Ocular Pharmacology of Antiviral Agents. EntoKey. Fastest Otolaryngology & Ophthalmology Insight Engine.
  17. Piret J, Boivin G. Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management. Curr Opin Infect Dis. 2016. Dec;29(6):654–62.
  18. Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS: Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections. Drugs. 1982 May;23(5):329-53.
  19. Wilhelmus KR (January 2015). Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis"The Cochrane Database of Systematic Reviews. 1 (1): CD002898
  20. Høvding G. A comparison between acyclovir and trifluorothymidine ophthalmic ointment in the treatment of epithelial dendritic keratitis. A double blind randomized parallel group trial. Acta Ophthalmol (Copenh) 1989 Feb;67(1):51-4. 
  21. Hoh HB, Hurley C, Claoue C, Viswalingham M, Easty DL et al. Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study. Br J Ophthalmol. 1996. Feb;80(2):140–3.
  22. Austin A, Lietman T, Rose-Nussbaumer J. Update on the Management of Infectious Keratitis. Ophthalmology. 2017;124(11):1678-1689.   
  23. Kalogeropoulos D, Geka A, Malamos K, et al. New therapeutic percep- tions in a patient with complicated herpes simplex virus 1 keratitis: a case report and review of the literature. Am J Case Rep 2017; 18: 1382 – 1389.
  24. Wilhelmus K. et al. Herpetic Eye Disease Study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology. 1994. Dec;101(12):1883–95–discussion 1895–6.  
  25. Barron BA, Gee L, Hauck WW, Kurinij N, Dawson CR, Jones DB. et al. Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. Ophthalmology. 1994. Dec;101(12):1871–82.  
  26. A controlled trial of oral acyclovir for iridocyclitis caused by herpes simplex virus. The Herpetic Eye Disease Study Group. Arch Ophthalmol. 1996. Sep;114(9):1065–72. 
  27. Wilhelmus KR, Beck RW, Moke PS, Dawson CR, Barron BA et al. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group. N Engl J Med. 1998. Jul 30;339(5):300–6. 
  28. Kim SR, Khan F, Ramirez-Fort MK, Downing C, Tyring SK. Varicella zoster: an update on current treatment options and future perspectives. Expert Opin Pharmacother. 2014. Jan;15(1):61–71. 
  29. Cobo LM, Foulks GN, Liesegang T, Lass J, Sutphin JE, Wilhelmus K. et al. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology. 1986. Jun;93(6):763–70. 
  30. Neoh C, Harding SP, Saunders D, Wallis S, Tullo AB, Nylander A. et al. Comparison of topical and oral acyclovir in early herpes zoster ophthalmicus. Eye. 1994;8 (Pt 6) (6):688–91.  
  31. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 1995. Jul;39(7):1546–53.
  32. Tyring S. et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med. 1995. Jul 15;123(2):89–96.
  33. Pepose JS, Ahuja A, Liu W,Haque R. Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis. Am J Ophthalmol. 2019. Sep;205:197.
  34. Ramakrishnan Set al. Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for the Treatment of Adenoviral Conjunctivitis. Am J Ophthalmol. 2019. Aug;204:140.
  35. "Cytomegalovirus retinitis". MedlinePlus Medical Encyclopedia. U.S. National Library of Medicine. Archived from the original on 2016-03-15. Retrieved 2016-03-14
  36. Tsui, Jonathan C.,Anton M. Miller, Charles G. Efficacy of Maribavir in Valganciclovir-Resistant Cytomegalovirus Retinitis. Retinal Cases & Brief Reports: Nov.16, 2022- 10.
  37. Jabs, D.A., et al. Cytomegalovirus resistance to ganciclovir and clinical outcomes of patients with cytomegalovirus retinitis. Am. J. Ophthalmol. 2003; 135:26–34
  38. Jabs, D.A., Martin, B.K., Ricks, M.O., Forman, M.S., and Cytomegalovirus Retinitis and Viral Resistance Study Group. Detection of ganciclovir resistance in patients with AIDS and cytomegalovirus retinitis: correlation of geno- typic methods with viral phenotype and clinical outcome. J. Infect. Dis. 2006; 193:1728–1737.
  39. Jabs, D.A., Enger, C., Forman, M., and Dunn, J.P. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group. Antimicrob. Agents Chemother. 1998; 42:2240–2244.
  40. Jabs, D.A., Enger, C., Dunn, J.P., and Forman, M. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group. J. Infect. Dis. 1998; 177:770–773.
  41. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med. 1992. Jan 23;326(4):213–20.
  42. Martin DF, Sierra-Madero J, Walmsley S, Wolitz RA, Macey K, Georgiou P. et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med. 2002. Apr 11;346(15):1119–26.
  43. Spector SA, Weingeist T, Pollard RB, Dieterich DT, Samo T, Benson CA. et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group. J Infect Dis. 1993. Sep;168(3):557–63.
  44. Miao H, Tao Y, Jiang Y-R, Li X-X. Multiple intravitreal injections of ganciclovir for cytomegalovirus retinitis after stem-cell transplantation. Graefes Arch Clin Exp Ophthalmol. 2013. Jul;251(7):1829–33.
  45. Sudharshan S, Ganesh SK, Biswas J (January 2010). "Current approach in the diagnosis and management of posterior uveitis". Indian Journal of Ophthalmology. 58 (1): 29–43.  
  46. Weiner G. "HIV-Related CMV Retinitis in the Developing World" (PDF). EyeNet Magazine - American Academy of Ophthalmology.2014, 27–29. Archived from the original (PDF) on 2023-03-07.
  47. Schoenberger SD, Kim SJ. et al. Diagnosis and Treatment of Acute Retinal Necrosis A Report by the American Academy of Ophthalmology. Ophthalmology. 2017. Mar 1;124(3):382–92. 
  48. Risseeuw S, de Boer JH, Ten Dam-van Loon NH. Risk of Rhegmatogenous Retinal Detachment in Acute Retinal Necrosis with and Without Prophylactic Intervention. Am J Ophthalmol. 2019 Oct; 206:140-148
  49. Chen M, Zhang M, Chen H. Eficiency of laser photocoagulation on the prevention of retinal detachment in acute retinal necrosis: A Systematic Review and Meta-Analysis. Retina. 2022 Sep 1;42(9):1702-1708
  50. Petrillo F, Petrillo A, Sasso FP, Schettino A, Maione A, Galdiero M. Viral Infection and Antiviral Treatments in Ocular Pathologies Microorganisms. 2022 Nov 10;10(11):2224

Capitolul 4

  1. Thomas, P. A. (2003). Fungal infections of the cornea . Eye, 17(8), 852-862.
  2. Kalkanci, A., & Ozdek, S. (2015) . Ocular Fungal Infections. 
  3. Pearlman, E., Leal, S. M., Tarabishy, A., Sun, Y., Szczotka-Flynn, L. B., Imamura, Y., Ghannoum, M. A. (2010). Pathogenesis of Fungal Keratitis.  
  4. Ng, J. K., Fraunfelder, F. W., & Winthrop, K. L. (2013). Review and Update on the Epidemiology, Clinical Presentation, Diagnosis, and Treatment of Fungal Keratitis. Current Fungal Infection Reports , 7(4), 293-300. 
  5. Hariprasad, S. M., Mieler, W. F., Lin, T. K., Sponsel, W. E., & Graybill, J. R. (2008). Voriconazole in the treatment of fungal eye infections: a review of current literature. British Journal of Ophthalmology, 92(7), 871-878. 
  6. Akler, M. E., Vellend, H., McNeely, D. M., Walmsley, S., & Gold, W. L. (1995). Use of Fluconazole in the Treatment of Candidal Endophthalmitis. Clinical Infectious Diseases, 20(3), 657-664. 
  7. Iyer, S. A., Tuli, S. S., & Wagoner, R. C. (2006). Fungal keratitis: emerging trends and treatment outcomes. Eye & Contact Lens-science and Clinical Practice , 32(6), 267-271. 
  8. Said, D. G., Otri, M. A., Miri, A., Kailasanathan, A., Khatib, T., & Dua, H. S. (2011). The challenge of fungal keratitis. British Journal of Ophthalmology, 95(12), 1623-1624. 
  9. Riddell, J., Comer, G. M., & Kauffman, C. A. (2011). Treatment of Endogenous Fungal Endophthalmitis: Focus on New Antifungal Agents. Clinical Infectious Diseases,52(5),648-653. 
  10. Callegan, M. C., Gregory-Ksander, M., Willcox, M. D., & Lightman, S. (2012). Ocular Inflammation and Infection. International Journal of Inflammation, 2012, 403520-403520 
  11. Malla, N., & Goyal, K. (2016). Ocular Parasitic Infections – An Overview. 
  12. Rathinam, S. R., & Kamath, Y. (2016). Ocular Parasitic Infections. 978-81-322-2295-8 13
  13. Padhi, T. R., Das, S., Sharma, S., Rath, S., Rath, S., Tripathy, D., Besirli, C. G. (2017). Ocular parasitoses: A comprehensive review. Survey of Ophthalmology, 62(2), 161-189. 
  14. 14. Braakenburg, A. M., & Rothova, A. (2016). Advances in Ocular Toxoplasmosis.  
  15. 15. Lindsay, R. G., Watters, G. A., Johnson, R., Ormonde, S. E., & Snibson, G. R. (2007). Acanthamoeba keratitis and contact lens wear. Clinical and Experimental Optometry, 90(5), 351-360 
  16. 16. Seal, D. V., Hay, J., Kirkness, C., Morrell, A. J., Booth, A. P., Tullo, A. B., Armstrong, M. (1996). Successful medical therapy of Acanthamoeba keratitis with topical chlorhexidine and propamidine. Eye, 10(4), 413-421 
  17. 17. Onchocerciasis (also known as River Blindness). (n.d.). CDC
  18. 18. Gicquel, J. (2008). Parasitic corneal infections. Acta Ophthalmologica, 87, 0-0.  

Capitolul 5

  1. Gaballa SA, Kompella UB, Elgarhy O, Alqahtani AM, Pierscionek B, Alany RG, Abdelkader H. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Deliv Transl Res. 2021 Jun;11(3):866-893 
  2. Kwatra G, Mukhopadhyay S. Topical corticosteroids: pharmacology, in a treatise on topical corticosteroids in dermatology 2018, Springer p 11–22
  3. Thakur A, Kadam RS, Kompella UB. Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids. Drug Metab Dispos. 2011;39(5):771–81
  4. Al-Muhammed J, et al. In-vivo studies on dexamethasone sodium phosphate liposomes. J Microencapsul. 1996;13(3):293–305
  5. Awan MA, et al. Penetration of topical and subconjunctival corticosteroids into human aqueous humour and its therapeutic significance. Br J Ophthalmol. 2009;93(6):708–13
  6. Musson D, Bidgood A, Olejnik O. An in vitro comparison of the permeability of prednisolone, prednisolone sodium phosphate, and prednisolone acetate across the NZW rabbit cornea. J Ocul Pharmacol Ther. 1992;8(2):139–50
  7. Agban Y, et al. Depot formulations to sustain periocular drug delivery to the posterior eye segment. Drug Discov Today. 2019;24(8):1458–69
  8. Salek SS, et al. Periocular triamcinolone acetonide injections for control of intraocular inflammation associated with uveitis. Ocul Immunol Inflamm. 2013;21(4):257–63
  9. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711–23
  10. Jiang CL, et al. The novel strategy of glucocorticoid drug development via targeting nongenomic mechanisms. Steroids. 2015;102:27–31.Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Rev Rheumatol. 2008;4(10):525
  11. Haller JA. Intravitreal corticosteroids: a review of therapeutic and surgical applications. Retina Today. 2009;S1:1–15
  12. ZhangX, et al. Glucocorticoids: structure, signaling and molecular mechanisms in the treatment of diabetic retinopathy and diabetic macular edema. Curr Mol Med. 2014;14:376–84
  13. Ayalasomayajula SP, Ashton P, Kompella UB. Fluocinolone inhibits VEGF expression via glucocorticoid receptor in human retinal pigment epithelial (ARPE-19) cells and TNF-α–induced angiogenesis in chick chorioallantoic membrane (CAM). J Ocul Pharmacol Ther. 2009;25(2):97–104
  14. Idrees F, et al. A review of anterior segment dysgeneses. Surv Ophthalmol. 2006;51(3):213–31
  15. McGhee C. Pharmacokinetics of ophthalmic corticosteroids. Br J Ophthalmol. 1992;76(11):681
  16. Pan Q, et al. Corticosteroid-loaded biodegradable nanoparticles for prevention of corneal allograft rejection in rats. J Control Release. 2015;201:32–40
  17. Ciulla TA, et al. Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Curr Opin Ophthalmol. 2004;15(3):211–20
  18. Bachu R, et al. Ocular drug delivery barriers—role of nanocarriers in the treatment of anterior segment ocular diseases. Pharmaceutics. 2018;10(1):28
  19. Gaudana R, et al. Ocular drug delivery. AAPS J. 2010;12(3):348–60
  20. Baranowski P, Karolewicz B, Gajda M, Pluta J. Ophthalmic drug dosage forms: Characterisation and research methods. Sci World J. 2014(2014):1–14
  21. Guy YJ, Friedman DI. Suspension of loteprednol etabonate for ear, eye, or nose treatment. 1996, Google Patents
  22. Ahmed I. The noncorneal route in ocular drug delivery, in Ophthalmic drug delivery systems. 2003, CRC Press. p. 356–385
  23. Kompella U, Vooturi S, Kadam R. Topical ocular drug delivery, 2013, Google Patents
  24. Gunda S, et al. Barriers in ocular drug delivery, in Ocular Transporters in Ophthalmic Diseases and Drug Delivery. 2008, Springer. p. 399–413
  25. Lang JC, Stiemke MM. Biological barriers to ocular delivery. Ocular Therapeutics and Drug Delivery. A Multi-disciplinary Approach, 1995: p. 51–132
  26. Davies NM. Biopharmaceutical considerations in topical ocular drug delivery. Clin Exp Pharmacol Physiol. 2000;27(7):558–62
  27. Lang JC. Ocular drug delivery conventional ocular formulations. Adv Drug Deliv Rev. 1995;16(1):39–43
  28. Hamashige S, Potts AM. The penetration of cortisone and hydrocortisone into the ocular structures. AmJ Ophthalmol. 1955;40(5): 211–6
  29. Gan L, et al. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone:improving preocular retention and ocular bioavailability. I J Pharm. 2010;396(1–2):179–87
  30. Gaballa SA, El Garhy OH, Abdelkader H. Cubosomes: composition, preparation, and drug delivery applications. J Adv Biomed Pharm Sci. 2020;3(1):1–9
  31. Abdelkader H, Alany RG. Controlled and continuous release ocular drug delivery systems: pros and cons. Curr Drug Deliv. 2012;9(4):421–30
  32. Green K, DOWNS SJ. Prednisolone phosphate penetration into and through the cornea. Invest Ophthalmol Vis Sci. 1974;13(4): 316–9
  33. Leibowitz HM, Kupferman A. Kinetics of topically administered prednisolone acetate: optimal concentration for treatment of inflammatory keratitis. Arch Ophthalmol. 1976;94(8):1387–9
  34. Flint GR,Morton DJ. Effect of derivatization of the bioavailability of ophthalmic steroids: development of an in vitro method of evaluation. Arch Ophthalmol. 1984;102(12):1808–9
  35. McGhee C, et al. Penetration of synthetic corticosteroids into human aqueous humour. Eye.1990;4:526–30
  36. Kristinsson JK, et al. Dexamethasone-cyclodextrin-polymer cocomplexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans. Invest Ophthalmol Vis Sci. 1996;37(6):1199–203
  37. Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol Vis Sci. 1965;4(2):198–205
  38. Hadayer A, Schaal S. Delivery of steroids into the eye for the treatment of macular edema. Exp Opin Drug Deliv. 2016;13(8): 1083–91
  39. Barar J, Javadzadeh AR, Omidi Y. Ocular novel drug delivery: impacts of membranes and barriers. Exp Opin Drug Deliv. 2008;5(5):567–81
  40. Waite D, et al. Posterior drug delivery via periocular route: challenges and opportunities. Ther Deliv. 2017;8(8):685–99.1985;100(1):114–8
  41. Urban RC Jr, Cotlier E. Corticosteroid-induced cataracts. Surv Ophthalmol. 1986;31(2):102–10
  42. Eisenstadt W, Cohen E. Osteoporosis and compression fracturesfrom prolonged cortisone and corticotropin therapy. Ann Allergy. 1955;13(3):252
  43. Stanbury RM, Graham EM. Systemic corticosteroid therapy—side effects and their management. Br J Ophthalmol. 1998;82(6): 704–8
  44. Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001;33(4):289–94
  45. Hyndiuk RA, Reagan MG. Radioactive depot-corticosteroid penetration into monkey ocular tissue: I. Retrobulbar and systemic administration. Arch Ophthalmol. 1968;80(4):499–503
  46. Barza M. Factors affecting the intraocular penetration of antibiotics. The influence of route, inflammation, animal species and tissue pigmentation. Scand J Infect Dis Suppl. 1978;14:151–9
  47. Tchernitchiv A, et al. Glucocorticoid localization by radioautography in the rabbit eye following systemic administration of 3H dexamethasone. Invest Ophthalmol Vis Sci. 1980;19(10):1231–6
  48. Hernandez M, et al. Corneal-conjunctival uptake of topical 3H-dexamethasone in the rabbit eye. Invest Ophthalmol Vis Sci. 1981;20(1):120–3
  49. Sherif Z, Pleyer U. Corticosteroids in ophthalmology: past–present– future. Ophthalmologica. 2002;216(5):305–15
  50. Yu W-K, et al. Ocular adnexal IgG4-related disease: clinical features, outcome, and factors associated with response to systemic steroids. Jpn J Ophthalmol. 2015;59(1):8–13
  51. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids. Drug Saf. 2002;25(1):33–55
  52. Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev. 2001;52(1):37–48
  53. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Exp Opin Drug Deliv. 2004;1(1):99–114
  54. Olsen TW, et al. Human sclera: thickness and surface area. Am J Ophthalmol. 1998;125(2):237–41
  55. Olsen TW, et al. Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci. 1995;36(9):1893–903
  56. Ambati J, et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci. 2000;41(5):1181–5
  57. Wen H, Hao J, Li SK. Influence of permeant lipophilicity on permeation across human sclera. Pharm Res. 2010;27(11):2446–56
  58. Janoria KG, et al. Novel approaches to retinal drug delivery. Exp Opin Drug Deliv. 2007;4(4):371–88.
  59. Akduman L, et al. Treatment of persistent glaucoma secondary to periocular corticosteroids. Am J Ophthalmol. 1996;122(2):275–7
  60. Nozik RA. Orbital rim fat atrophy after repository periocular corticosteroid injection. Am J Ophthalmol. 1976;82(6):928–30
  61. Weijtens O, et al. Dexamethasone concentration in the subretinal fluid after a subconjunctival injection, a peribulbar injection, or an oral dose. Ophthalmology. 2000;107(10):1932–8
  62. Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano-and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci. 2003;44(3):1192–201
  63. Leibowitz HM, Kupferman A. Periocular injection of corticosteroids: an experimental evaluation of its role in the treatment of corneal inflammation. Arch Ophthalmol. 1977;95(2):311–4
  64. Hosseini K, et al. Pharmacokinetic study of dexamethasone disodium phosphate using intravitreal, subconjunctival, and intravenous delivery routes in rabbits. J Ocul Pharmacol Ther. 2008;24(3):301–8
  65. McCartney H, et al. An autoradiographic study of the penetration of subconjunctivally injected hydrocortisone into the normal and inflamed rabbit eye. Invest Ophthalmol Vis Sci. 1965;4(3):297– 302
  66. Pendergast SD, Eliott D, Machemer R. Retinal toxic effects following inadvertent intraocular injection of Celestone Soluspan. Arch Ophthalmol. 1995;113(10):1230–1
  67. Fischer C. Granuloma formation associated with subconjunctival injection of a corticosteroid in dogs. J Am Vet Med Assoc. 1979;174(10):1086–8
  68. Herrero-Vanrell R, et al. Sustained back of the eye delivery following sub-tenon administration of dexamethasone-loaded PLGA microspheres in rabbits. Invest Ophthalmol Vis Sci. 2012;53(14): 477
  69. Das D, Serasiya S, Misra D. Complications and safety profile of posterior sub-tenon triamcinolone injections in sclero-uveitis cases in a tertiary institute of northeast India. Adv Ophthalmol Vis Syst. 2018;8(6):231–2
  70. Lafranco DafflonM, et al. Posterior sub-Tenon’s steroid injections for the treatment of posterior ocular inflammation: indications, efficacy and side effects. Graefes Arch Clin Exp Ophthalmol. 1999;237(4):289–95
  71. Cardillo JA, et al. Comparison of intravitreal versus posterior sub– Tenon’s capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology. 2005;112(9):1557–63
  72. Kim MW, et al. Effect of posterior subtenon triamcinolone acetonide injection on diabetic macular edema refractory to intravitreal bevacizumab injection. Korean J Ophthalmol. 2016;30(1): 25–31
  73. Ripart J, et al. Peribulbar versus retrobulbar anesthesia for ophthalmic surgery an anatomical comparison of extraconal and intraconal injections. Anesthesiology. 2001;94(1):56–62
  74. Herschler J. Intractable intraocular hypertension induced by repository triamcinolone acetonide. Am J Ophthalmol. 1972;74(3): 501–4
  75. Olsen TW, et al. Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment. Am J Ophthalmol. 2006;142(5):777–787 
  76. Soiberman U, et al. Subconjunctival injectable dendrimerdexamethasone gel for the treatment of corneal inflammation. Biomaterials. 2017;125:38–53
  77. Gillies MC, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004;122(3):336–40
  78. Hartman RR, Kompella UB. Intravitreal, subretinal, and suprachoroidal injections: evolution of microneedles for drug delivery. J Ocul Pharmacol Ther. 2018;34(1–2):141–53
  79. Wang B, et al. Efficacy and safety of intracameral triamcinolone acetonide to control postoperative inflammation after phacotrabeculectomy. J Cataract Refract Surg. 2013;39(11): 1691–7
  80. Simaroj P, Sinsawad P, Lekhanont K. Effects of intracameral triamcinolone and gentamicin injections following cataract surgery. J Med Assoc Thail. 2011;94(7):819
  81. CunninghamMA, Edelman JL, Kaushal S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv Ophthalmol. 2008;53(2):139–49
  82. Doshi RR, Bakri SJ, Fung AE. Intravitreal injection technique. In Seminars in ophthalmology. 2011. Taylor & Francis.
  83. Mitra AK, Anand BS, Duvvuri S. Drug delivery to the eye. Adv Organ Biol. 2005;10:307–51
  84. Durairaj C, et al. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure–pharmacokinetic relationships (QSPKR). Pharm Res. 2009;26(5):1236
  85. Beer PM, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110(4):681–6
  86. Graham RO, Peyman GA. Intravitreal injection of dexamethasone: treatment of experimentally induced endophthalmitis. Arch Ophthalmol. 1974;92(2):149–54
  87. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide
  88. Zacharias LC, et al. Assessment of the differences in pharmacokinetics and pharmacodynamics between four distinct formulations of triamcinolone acetonide. Retina. 2013;33(3):522–31
  89. RazeghinejadMR, Katz LJ. Steroid-induced iatrogenic glaucoma. Ophthalmic Res. 2012;47(2):66–80
  90. Mansoor S, Kuppermann BD, Kenney MC. Intraocular sustained release delivery systems for triamcinolone acetonide. Pharm Res. 2009;26(4):770–84
  91. Cao Y, et al. Recent advances in intraocular sustained-release drug delivery devices. Drug Discov Today. 2019;24(8):1694–700
  92. Allergan I. OZURDEX®product information, I. Allergan, Editor 2014, Allergan, Inc
  93. Malclès A, et al. Safety of intravitreal dexamethasone implant (Ozurdex): the SAFODEX study. Incidence and risk factors of ocular hypertension. Retina. 2017;37(7):1352–9
  94. Jaffe GJ, et al. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000;107(11): 2024–33
  95. Driot J-Y, et al. Ocular pharmacokinetics of fluocinolone acetonide after Retisert™intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther. 2004;20(3):269–75
  96. Kane FE, Green KE. Ocular pharmacokinetics of fluocinolone acetonide following Iluvien implantation in the vitreous humor of rabbits. J Ocul Pharmacol Ther. 2015;31(1):11–6
  97. Sanford M. Fluocinolone acetonide intravitreal implant (Iluvien®). Drugs. 2013;73(2):187–93
  98. Parekh A, et al. Risk factors associated with intraocular pressure increase in patients with uveitis treated with the fluocinolone acetonide implant. JAMA Ophthalmol. 2015;133(5):568–73
  99. Cholkar K, et al. Novel strategies for anterior segment ocular drug delivery. J Ocul Pharmacol Ther. 2013;29(2):106–23 
  100. Tamura H, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci. 2005;46(4):1440–4
  101. Peeters L, et al. Vitreous: a barrier to nonviral ocular gene therapy. Invest Ophthalmol Vis Sci. 2005;46(10):3553–61
  102. Thakur SS, et al. Intravitreal drug delivery in retinal disease: are we out of our depth? Exp Opin Drug Deliv. 2014;11(10):1575–90
  103. Schmit-Eilenberger VK. A novel intravitreal fluocinolone acetonide implant (Iluvien®) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series. Clin Ophthalmol. 2015;9:801
  104. Kiddee W, et al. Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol. 2013;58(4):291–310
  105. Abraldes MJ, Fernández M, Gómez-Ulla F. Intravitreal triamcinolone in diabetic retinopathy. Curr Diabetes Rev. 2009;5(1):18–25
  106. Gilger BC, et al. Long-term outcome after implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis. Vet Ophthalmol. 2010;13(5):294–300
  107. Clearside Biomedical, I. Clearside Biomedical revises NDA resubmission timeline and XIPERE™commercial partnership with Bausch Health. 2020 ;cited August 2020.
  108. Goldstein DA, et al. Suprachoroidal corticosteroid administration: a novel route for local treatment of noninfectious uveitis. Translat Vision Sci Technol. 2016;5(6):14
  109. Edelhauser HF, et al. Intraocular distribution and targeting of triamcinolone acetonide suspension administered into the suprachoroidal space. Invest Ophthalmol Vis Sci. 2014;55(13): 5259
  110. Patel SR, et al. Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm Res. 2011;28(1):166–76
  111. Gilger BC, et al. Treatment of acute posterior uveitis in a porcine model by injection of triamcinolone acetonide into the suprachoroidal space using microneedles. Invest Ophthalmol Vis Sci. 2013;54:2483–92
  112. Kuriakose T, et al. Intracameral amphotericin B injection in the management of deep keratomycosis. Cornea. 2002;21(7):653–6
  113. Tan DT, et al. Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation. Ophthalmology. 1999;106(2):223–31
  114. Jonas J, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol. 2003;87(1):24–7
  115. Krupin T, et al. Uveitis in association with topically administered corticosteroid. Am Ophthalmol. 1970;70(6):883–5
  116. Parekh A, et al. Risk factors associated with intraocular pressure increase in patients with uveitis treated with the fluocinolone acetonide implant. JAMA Ophthalmol. 2015;133(5):568–73
  117. Tripathi RC, et al. Corticosteroids and glaucoma risk. Drugs Aging. 1999;15(6):439–50
  118. Clark AF, et al. Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes. Invest Ophthalmol Vis Sci. 1995;36(2):478–89
  119. Hernandez MR, et al.Glucocorticoid target cells in human outflow pathway: autopsy and surgical specimens. Invest Ophthalmol Vis Sci. 1983;24(12):1612–6
  120. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics: I. The effect of dexamethasone* in the normal eye. Arch Ophthalmol. 1963;70(4):482–91
  121. Spaeth GL, Rodrigues MM, Weinreb S. Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B Histopathological aspects. Trans Am Ophthalmol Soc. 1977;75: 353
  122. Smith C. Corticosteroid glaucoma: a review of the literature. Am J Med Sci. 1966;252:239–44
  123. Pleyer U, Ursell PG, Rama P. Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same? Ophthalmol Therapy. 2013;2:55–72
  124. Lam DS, et al. Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. Clin Exp Ophthalmol. 2005;33(3):252–8
  125. Kwok AK, et al. Ocular-hypertensive response to topical steroids in children. Ophthalmology. 1997;104(12):2112–6
  126. Mindel JS, et al. Comparative ocular pressure elevation by medrysone, fluorometholone, and dexamethasone phosphate. Arch Ophthalmol. 1980;98(9):1577–8
  127. Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol. 2000;11(6):478–83
  128. Agban Y, et al. Depot formulations to sustain periocular drug delivery to the posterior eye segment. Drug Discov Today. 2019;24(8):1458–69
  129. Cantrill HL, et al. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol. 1975;79(6):1012–7
  130. Nuyen B,Weinreb RN, Robbins SL. Steroid-induced glaucoma in the pediatric population. J Am Assoc Pediatr Ophthalmol Strabismus. 2017;21(1):1–6
  131. Donnenfeld ED, et al. A multicenter randomized controlled fellow eye trial of pulse-dosed difluprednate 0.05% versus prednisolone acetate 1% in cataract surgery. Am J Ophthalmol. 2011;152(4): 609–617
  132. Herschler J. Increased intraocular pressure induced by repository corticosteroids. Am J Ophthalmol. 1976;82(1):90–3
  133. Whitcup SM, et al. Pharmacology of corticosteroids for diabetic macular edema. Invest Ophthalmol Vis Sci. 2018;59(1):1–12
  134. Parente L. Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids. BMC Pharmacol Toxicol. 2017;18(1):1
  135. Wilson M. Epidemiology of chronic open-angle glaucoma. Glaucomas. 1996;2:753–68
  136. Stárka L, Hampl R, Obenberger J. Corticosterone in the aqueous humour of the rabbit eye. J Steroid Biochem. 1972;3(1):39–42
  137. Jones R, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006;17:163–7
  138. Jobling AI, Augusteyn RC. What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. Clin Exp Optom. 2002;85(2):61–75
  139. Bodor N, Buchwald P. Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J. 2005;7(4):820–33
  140. Bucala R, et al. Glucocorticoid-lens protein adducts in experimentally induced steroid cataracts. Exp Eye Res. 1985;40(6):853–63
  141. Bucala R, et al. Nonenzymatic modification of lens crystallins by prednisolone induces sulfhydryl oxidation and aggregate formation: in vitro and in vivo studies. Exp Eye Res. 1985;41(3):353–63
  142. Deshmukh C. Minimizing side effects of systemic corticosteroids in children. Indian J Dermatol Venereol Leprol. 2007;73(4):218
  143. Ohta Y, et al. Anticataract action of vitamin E: its estimation using an in vitro steroid cataract model. Ophthal Lit. 1997;1(50):21
  144. Samadi A. Steroid-induced cataract. In: Levin LA, Albert DM, editors. Ocular Disease: Mechanism and Management. USA: Saunders, Elsevier; 2010. p. 250–7
  145. Hengge UR, et al. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1–15
  146. Goñi FJ, et al. Elevated intraocular pressure after intravitreal steroid injection in diabetic macular edema: monitoring and management. Ophthalmol Therapy. 2016;5(1):47–61
  147. Pereira F, et al. Systemic absortion and adverse effects of topical ocular use of ketorolac tromethamine and sodium diclofenac in New Zealand rabbits for 90 days. Arquivo Brasileiro de Medicina Veterinária e Zootecnia. 2019;71(6):1865–72
  148. Eljarrat-Binstock E, Domb AJ. Iontophoresis: a non-invasive ocular drug delivery. J Control Release. 2006;110(3):479–89
  149. Kompella UB, et al. Ocular drug delivery: nanotechnology, physical and chemical methods, vitreous drug binding, and aging eye. J Ocular Pharmacol Ther, 2019
  150. Patane M, et al. Randomized, double-masked study of four iontophoresis dose levels of EGP-437 in non-infectious anterior segment uveitis subjects. Invest Ophthalmol Vis Sci. 2010;51(13): 5263
  151. Friedman NJ, Kaiser PK. Ocular pharmacology. In: Essentials of Ophthalmology. Philadelphia: Elsevier; 2007:25-32
  152. MB, Butrus S. Corticosteroids in ophthalmic practice. Chapter 23. In: Albert DM et al., eds. Albert & Jakobiec’s Principles and Practice of Ophthalmology, 3rd ed. Philadelphia: Saunders Elsevier; 2008

Capitolul 6

  1. Costagliola, Ciro et al. “Topical and oral ketorolac administration increases the intraocular pressure-lowering effect of latanoprost.” Current eye researchvol. 33,5 (2008): 477-82. doi:10.1080/02713680802100845
  2. Costagliola, Ciro et al. “The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients.” Experimental eye research vol. 81,5 (2005): 610-5. doi: 10.1016/j.exer.2005.03.020
  3. Kraff, M C et al. “Efficacy of diclofenac sodium ophthalmic solution versus placebo in reducing inflammation following cataract extraction and posterior chamber lens implantation.” Journal of cataract and refractive surgery vol. 20,2 (1994): 138-44. doi:10.1016/s0886-3350(13)80153-8
  4. Gamache, D A et al. “Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy.” Inflammation vol. 24,4 (2000): 357-70. doi:10.1023/a:1007049015148
  5. Waterbury, L David et al. “Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium.” Current medical research and opinion vol. 22,6 (2006): 1133-40. doi:10.1185/030079906X112471
  6. Ahuja, Munish et al. “Topical ocular delivery of NSAIDs.” The AAPS journal vol. 10,2 (2008): 229-41. doi:10.1208/s12248-008-9024-9
  7. Roberts, C W. “Comparison of diclofenac sodium and flurbiprofen for inhibition of surgically induced miosis.” Journal of cataract and refractive surgeryvol. 22 Suppl 1 (1996): 780-7. doi:10.1016/s0886-3350(96)80162-3
  8. Blaydes, J E Jr et al. “Flurbiprofen 0.03% for the control of inflammation following cataract extraction by phacoemulsification.” Journal of cataract and refractive surgery vol. 19,4 (1993): 481-7. doi:10.1016/s0886-3350(13)80611-6
  9. Ke, T L et al. “Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers.” Inflammation vol. 24,4 (2000): 371-84. doi:10.1023/a:1007001131987
  10. Walters, Tom et al. “In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.” Journal of cataract and refractive surgery vol. 33,9 (2007): 1539-45. doi: 10.1016/j.jcrs.2007.05.015
  11. Bucci, Frank A Jr et al. “Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification.” American journal of ophthalmology vol. 144,1 (2007): 146-7. doi: 10.1016/j.ajo.2007.02.034
  12. Green, K et al. “Penetration of topical indomethacin into phakic and aphakic rabbit eyes.” Archives of ophthalmology (Chicago, Ill.: 1960) vol. 101,2 (1983): 284-8. doi:10.1001/archopht.1983.01040010286021
  13. Rabiah, P K et al. “Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis.” Investigative ophthalmology & visual sciencevol. 37,4 (1996): 613-8.
  14. Gamache, D A et al. “Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy.” Inflammation vol. 24,4 (2000): 357-70. doi:10.1023/a:1007049015148
  15. Baklayan, George A et al. “24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits.” Journal of ocular pharmacology and therapeutics: the official journal of the Association for Ocular Pharmacology and Therapeutics vol. 24,4 (2008): 392-8. doi:10.1089/jop.2007.0082
  16. Flach, Allan Joseph. “Topical nonsteroidal antiinflammatory drugs in ophthalmology.” International ophthalmology clinics vol. 42,1 (2002): 1-11. doi:10.1097/00004397-200201000-00003
  17. Kim, Stephen J et al. “Topical ketorolac in vitreoretinal surgery: a prospective, randomized, placebo-controlled, double-masked trial.” Archives of ophthalmology (Chicago, Ill.: 1960) vol. 126,9 (2008): 1203-8. doi:10.1001/archopht.126.9.1203
  18. Vander, J F et al. “Flurbiprofen sodium to prevent intraoperative miosis during vitreoretinal surgery.” American journal of ophthalmology vol. 108,3 (1989): 288-91. doi:10.1016/0002-9394(89)90119-0
  19. Kulshrestha, M K et al. “The role of preoperative subconjunctival mydricaine and topical diclofenac sodium 0.1% in maintaining mydriasis during vitrectomy.” Retina (Philadelphia, Pa.) vol. 20,1 (2000): 46-51. doi:10.1097/00006982-200001000-00009
  20. Holland EJ. Non-invasive punctal plug delivery system offers a host of positive performance characteristics. Ophthalm. Times mar 2017
  21. Donnenfeld, Eric D et al. “Intracameral ketorolac and phenylephrine effect on intraoperative pupil diameter and postoperative pain in cataract surgery.” Journal of cataract and refractive surgery vol. 43,5 (2017): 597-605. doi: 10.1016/j.jcrs.2017.02.030
  22. Lobo, Conceição L et al. “Macular alterations after small-incision cataract surgery.” Journal of cataract and refractive surgery vol. 30,4 (2004): 752-60. doi:10.1016/S0886-3350(03)00582-0
  23. Ahmadieh, Hamid et al. “Anatomic and visual outcomes of scleral buckling versus primary vitrectomy in pseudophakic and aphakic retinal detachment: six-month follow-up results of a single operation--report no. 1.” Ophthalmology vol. 112,8 (2005): 1421-9. doi: 10.1016/j.ophtha.2005.02.018
  24. Pole, Cameron et al. “Macular edema after rhegmatogenous retinal detachment repair: risk factors, OCT analysis, and treatment responses.” International journal of retina and vitreous vol. 7,1 9. 25 Jan. 2021, doi:10.1186/s40942-020-00254-9
  25. Staudt, S et al. “Inzidenz und Ausprägung von postoperativem Makulaödem nach Makulaforamenoperation mit und ohne kombinierte Kataraktoperation” [Incidence and extent of postoperative macular edema following vitreoretinal surgery with and without combined cataract operation]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft vol. 100,9 (2003): 702-7. doi:10.1007/s00347-003-0821-3
  26. Kim, Stephen J et al. “Topical ketorolac in vitreoretinal surgery: a prospective, randomized, placebo-controlled, double-masked trial.” Archives of ophthalmology (Chicago, Ill. : 1960) vol. 126,9 (2008): 1203-8. doi:10.1001/archopht.126.9.1203
  27. Flach, Allan Joseph. “Topical nonsteroidal antiinflammatory drugs in ophthalmology.” International ophthalmology clinics vol. 42,1 (2002): 1-11. doi:10.1097/00004397-200201000-00003
  28. Flach AJ. Nonsteroidal anti-inflammatory drugs. In Tasman W (ed): Duanes Foundations of Clinical Ophthalmology, vol. 2. Philadelphia, PA, Lippincott, 1994, pp. 1-32
  29. Donnenfeld, Eric D et al. “Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.” Ophthalmology vol. 114,9 (2007): 1653-62. doi: 10.1016/j.ophtha.2006.12.029
  30. Donnenfeld, Eric D et al. “Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curve.” Journal of cataract and refractive surgery vol. 32,9 (2006): 1474-82. doi: 10.1016/j.jcrs.2006.04.009
  31. Leopold, I H. “Advances in ocular therapy: noncorticosteroid anti-inflammatory agents. Fifth annual Jules Stein Lecture.” American journal of ophthalmology vol. 78,5 (1974): 759-73. doi:10.1016/0002-9394(74)90298-0
  32. Miyake-Kashima, Minori et al. “Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis.” Japanese journal of ophthalmology vol. 48,6 (2004): 587-90. doi:10.1007/s10384-004-0127-2
  33. Adamis, Anthony P, and Adrienne J Berman. “Immunological mechanisms in the pathogenesis of diabetic retinopathy.” Seminars in immunopathologyvol. 30,2 (2008): 65-84. doi:10.1007/s00281-008-0111-x
  34. Joussen, Antonia M et al. “Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression.” FASEB journal: official publication of the Federation of American Societies for Experimental Biology vol. 16,3 (2002): 438-40. doi: 10.1096/fj.01-0707fje
  35. Kern, Timothy S et al. “Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology.” Diabetes vol. 56,2 (2007): 373-9. doi:10.2337/db05-1621
  36. Nikkhah, Homayoun et al. “Topical ketorolac as an adjunctive treatment with intravitreal bevacizumab in the management of diabetic macular edema: A double-masked placebo-controlled randomized clinical trial.” Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie vol. 259,10 (2021): 2949-2959. doi:10.1007/s00417-021-05169-1
  37. Song, Seok Hyeon et al. “Effect of 0.1% Bromfenac for Preventing Macular Edema after Cataract Surgery in Patients with Diabetes.” Korean journal of ophthalmology: KJO vol. 34,1 (2020): 46-55. doi:10.3341/kjo.2019.0044
  38. Gabr, Ahmed F et al. “Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for diabetic macular edema.” International ophthalmology vol. 43,9 (2023): 3219-3226. doi:10.1007/s10792-023-02722-1
  39. Yao, Yang et al. “Interleukin-6 and Diabetic Retinopathy: A Systematic Review and Meta-Analysis.” Current eye research vol. 44,5 (2019): 564-574. doi:10.1080/02713683.2019.1570274
  40. Gupta, Dhanu et al. “Modulation of Pro-Inflammatory IL-6 Trans-Signaling Axis by Splice Switching Oligonucleotides as a Therapeutic Modality in Inflammation.” Cells vol. 12,18 2285. 15 Sep. 2023, doi:10.3390/cells12182285
  41. Sharma, Shruti. “Interleukin-6 Trans-signaling: A Pathway with Therapeutic Potential for Diabetic Retinopathy.” Frontiers in physiology vol. 12 689429. 19 May. 2021, doi:10.3389/fphys.2021.689429
  42. Lin, J C et al. “Corneal melting associated with use of topical nonsteroidal anti-inflammatory drugs after ocular surgery.” Archives of ophthalmology (Chicago, Ill.: 1960) vol. 118,8 (2000): 1129-32.
  43. Bekendam, Peter D et al. “Case of corneal melting associated with the use of topical nepafenac.” Cornea vol. 26,8 (2007): 1002-3. doi:10.1097/ICO.0b013e3180cfe626

Capitolul 7

  1. Bartlett, J. D., & Jaanus, S. D. Clinical Ocular Pharmacology (5th ed.). Boston: Butterworth-Heinemann, 2008, pg. 125-138.
  2. Gedar Totuk OM, Altinel MG, Kanra AY. Clinical value of phenylephrine testing in the upper and lower eyelids of patients with aponeurotic and congenital eyelid ptosis. Int J Ophthalmol. 2022;15(9):1444-1452. 
  3. Dutta Majumder P, Agrawal R, McCluskey P, Biswas J. Current Approach for the Diagnosis and Management of Noninfective Scleritis. Asia Pac J Ophthalmol (Phila). 2020 Dec 7;10(2):212-223. 
  4. Wilson S, Ctori I, Shah R, Suttle C, Conway ML. Systematic review and meta-analysis on the agreement of non-cycloplegic and cycloplegic refraction in children. Ophthalmic Physiol Opt. 2022;42(6):1276-1288.
  5. Fong, D. S. Drugs in Ophthalmology (2nd ed.). Boston: Jones and Bartlett Publishers, 2009, pg. 16, 50-51,118,175,201.
  6. Jalin AJ, Julius TO. Pharmacologic Mydriasis and Cycloplegia: A Review of Novel Delivery Devices. touchREVIEWS in Ophthalmology. 2023;17(2):19–22.
  7. Chia A, Lu QS, Tan D. Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2: Myopia Control with Atropine 0.01% Eyedrops. Ophthalmology. 2016;123(2):391-399. doi: 10.1016/j.ophtha.2015.07.004
  8. Major E, Dutson T, Moshirfar M. Cycloplegia in Children: An Optometrist's Perspective. Clin Optom (Auckl). 2020; 12:129-133.

Capitolul 8

  1. Stein HA, Stein RM, Freeman MI. The Ophthalmic Assistant E-Book: A Text for Allied and Associated Ophthalmic Personnel. Elsevier Health Sciences; 2017. 929 p.
  2. Hopkins, G., & Pearson, R. Ophthalmic drugs: Diagnostic and Therapeutic Uses. Butterworth-Heinemann, 2007.
  3. Vanderah TW. Katzung's Basic and Clinical Pharmacology, 16th Edition. 16th edition. New York Chicago San Francisco Athens London Madrid Mexico City Milan New Delhi Singapore Sydney Toronto: McGraw Hill / Medical; 2023. 1368 p.
  4. Kaushik J., Sharma R., Goyal S., Dangi M., Jha R., & Singh A. Alpha-adrenergic antagonists and iris dynamics: challenges and solutions in cataract surgery. BMC Ophthalmology 2024;24(1).
  5. Stamper, R. L., Lieberman, M. F., Drake, M. V., & Becker, B., Becker-Shaffer’s Diagnosis and Therapy of Glaucomas. Elsevier Health Sciences, 2009.
  6. Kahook, M., & Schuman, J. S. Chandler and Grant’s Glaucoma. CRC Press, 2024.
  7. Pilocarpine Eye Drops 1%, 2% and 4%. 
  8. MIOSTAT TM Intraocular Solution for Injection.   
  9. Miochol®-E acetylcholine chloride. 
  10. Davies PHO. The Actions and Uses of Ophthalmic Drugs: Third Edition. Butterworth-Heinemann; 2014. 262 p.
  11. Fong DS, Law SK, Schmidt-Erfurth UM. Drugs in Ophthalmology. Springer; 2008. 248
  12. Waring GO IV, Price FW Ir. Wirta D. McCabe C, Moshirlar M. Guo Q, et al. Safety and Efficacy of AGN-190584 in Individuals with Presbyopia: The GEMINI 1 Phase 3 Randomized Clinical Trial. JAMA Ophthalmology. 2022 Apr 1:140(4):363-71.
  13. Holland E, Karpecki P, Fingeret M. Schaeffer J, Gupta P, Fram N, et al. Efficacy and Safety of CSF-1 (0.4% Pilocarpine Hydrochloride) in Presbyopia: Pooled Results of the NEAR Phase 3 Randomized, Clinical Trials. Clin Ther. 2024 Feb;46(2): 104-13.
  14. Grzybowski A. Ruamviboonsuk V. Pharmacological Treatment in Presbyopia. Journal of Clinical Medicine. 2022 Mar 3;11(5): 1385.
  15. Grzybowski A, Markeviciute A, Zemaitiene R. A Review of Pharmacological Presbyopia Treatment. Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa). 2020 Jun 4;9(3):226.
  16. Kannarr S, El-Harazi SM, Moshirfar M, Lievens C, Kim JL, Peace JH, et al. Safety and Efficacy of Twice-Daily Pilocarpine HCI in Presbyopia: The Virgo Phase 3, Randomized, Double-Masked, Controlled Study. American Journal of Ophthalmology. 2023 Sep 1; 253:189-200.

Capitolul 9

1. European Glaucoma Society. Terminology and Guidelines for Glaucoma. 5th edition. 2021

2.Gedde SJ, Vinod K, Wright MM, Muir KW, Lind JT, Chen PP, et al. American Academy of Ophthalmology Preferred Practice Pattern Glaucoma Panel. Primary Open-Angle Glaucoma Preferred Practice Pattern®. Ophthalmology.2020;128(1): P71-150

3.Gazzard, G. ∙ Konstantakopoulou, E. ∙ Garway-Heat. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial,Lancet. 2019; 393:1505-1516

4.Takusagawa HL, Hoguet A, Sit AJ, Rosdahl JA, Chopra V, Ou Y, et al. Selective Laser Trabeculoplasty for the Treatment of Glaucoma: A Report by the American Academy of Ophthalmology. Ophthalmology. 2024;131(1):37–47

5. Chavez MP, Guedes GB, Pasqualotto E, Lopes LM, Ferreira ROM, De Souza ESMV, et al. Selective laser trabeculoplasty versus medical therapy for thetreatment of open angle glaucoma or ocular hypertension: a systematic review and meta-analysis of randomized controlled trials. J Glaucoma.2024;33(12):973–86

6.Shalini Virani,Parveen Rewri. A Narrative Review of Pharmacotherapy of Glaucoma Future Pharmacol. 2024, 4(2), 395-419

7.Leinonen S, Harju M, Hagman J, Honkamo M, Marttila L, Mätä M, et al. The Finnish current care guideline for open-angle glaucoma. Acta Ophthalmol.2024;102(2):151–171

8.Lee, P.W.; Doyle, A.; Stewart, J.A.; Kristoffersen, C.J.; Stewart, W.C. Meta-analysis of timolol on diurnal and nighttime intraocular pressure and blood pressure. Eur. J. Ophthalmol. 2010, 20, 1035–1041

9.Leung DYL, Tham CC. Normal-tension glaucoma: Current concepts and approaches-A review. Clin Exp Ophthalmol. 2022 Mar;50(2):247-259

10 Supuran CT, Altamimi ASA, Carta F. Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019. Expert Opin Ther Pat. 2019 Oct;29(10):781-792

11.Samaha, D.; Diaconu, V.; Bouchard, J.F.; Desalliers, C.; Dupont, A. Effect of latanoprostene bunod on optic nerve head blood flow. Optom. Vis. Sci. 2022, 99, 172–176

12.Lin, L.; Zhao, Y.J.; Chew, P.T.; Sng, C.C.; Wong, H.T.; Yip, L.W.; Wu, T.S.; Bautista, D.; Teng, M.; Khoo, A.L.; et al. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension. Ann. Pharmaco. 2014, 48, 1585–1593

13.Cai, Z.; Cao, M.; Liu, K.; Duan, X. Analysis of the responsiveness of latanoprost, travoprost, bimatoprost, and tafluprost in the Treatment of OAG/OHT patients. J. Ophthalmol. 2021, 55,86-79

14.Thomas, N.M.; Nagrale, P. Rho Kinase inhibitors as a neuroprotective pharmacological intervention for the treatment of Glaucoma. Cureus 2022, 14, 34

15.Clement Freiberg, J.; von Spreckelsen, A.; Kolko, M.; Azuara-Blanco, A.; Virgili, G. Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension. Cochrane Database Syst. Rev. 2022, 6, 26

16.Aihara M, Ropo A, Lu F, Kawata H, Iwata A, Odani-Kawabata N, Shams N. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study. Jpn J Ophthalmol. 2020 Jul;64(4):398-406

17.Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A. Omidenepag isopropyl in latanoprost low/non-responders with primary open-angle glaucoma or ocular hypertension: a phase 3, non-randomized, two-phase, open-label study. J Glaucoma. 2023 Oct 17;32(12):999–1005

18. Diagourtas A, Kagelaris K, Oikonomakis K, Droulias A, Kokolakis N, Papaconstantinou D. Prospective study comparing Xalatan eye drops and two similar generics as to the efficacy and safety profile. Eur J Ophthalmol. 2018;28(4):378-384

19.Tatham AJ. The use of generic medications for glaucoma. J Ophthalmol.2020;1651265. doi:10.1155/2020/1651265

20.Steven DW, Alaghband P, Lim KS. Preservatives in glaucoma medication. Br J Ophthalmol 2018 Nov; 102: 1497–1503

21.Pilar Pérez-García, Bárbara Burgos-Blasco and Jose María Martinez-de-la-Casa. Prescription trends for preservative free glaucoma medication in a public health system;European Journal of Ophthalmology, 2024,Volume 34, (1) ,23-29,

22. Skov AG, Rives AS, Freiberg J, Virgili G, Azuara-Blanco A, Kolko M. Comparative efficacy and safety of preserved versus preservative-free beta-blockers in patients with glaucoma or ocular hypertension: a systematic review. Acta Ophthalmol. 2022 May;100(3):253-261

23.Seibold, L.K.; DeWitt, P.E.; Kroehl, M.E.; Kahook, M.Y. The 24-hour effects of brinzolamide/brimonidine fixed combination and timolol on intraocular pressure and ocular perfusion pressure. J. Ocul. Pharmacol. Ther. 2017, 33, 161–169

24, Toumanidou, V.; Diafas, A.; Georgiadis, N.; Tsinopoulos, I. Fixed versus unfixed combination of topical latanoprost/timolol for glaucoma: an observational study investigating the level of adherence and ocular surface health. J. Clin. Med. 2023, 12, 3137.

25, Menon, M.G.; Goodkin, M.L. Triple Fixed-Combination bimatoprost/brimonidine/timolol in glaucoma and ocular hypertension in india: a multicenter, open-label, phase 3 study. Clin. Ophthalmol. 2022, 16, 3559–3569

26.Avinash Mishra  , Mohini Agrawal  , Anchal Tripathi , Atul Bhirud  , Lt Col Rajnish Kumar  , Brig Baranwal Vinod K .A comparative study on efficacy of intraocular pressure lowering of two fixed-dose antiglaucoma drug combination brinzolamide-brimonidine versus latanoprost-timolol in primary open-angle glaucoma and ocular hypertension J Ocul Pharmacol Ther . 2024 May;40(4):240-245

27 Konstas, A.G.; Schmetterer, L.; Costa, V.P.; Holló, G.; Katsanos, A.; Denis, P.; Quaranta, L.; Irkec, M.; Castejón, M.A.; Teus, M.A.; et al. Current and emerging fixed combination therapies in glaucoma: A safety and tolerability review. Expert Opin. Drug Saf. 2020, 19, 1445–1460

28.Holló, G. Ocular hyperemia associated with topical glaucoma medication: understanding and differentiating clinical appearance and underlying mechanisms. Expert Opinion on Drug Safety, 2024 ,24(2), 145–156

29.Sakata, R., Chang, P. Y., Sung, K. R., Kim, T. W., Wang, T. H., Perera, S. A., & Cantor, L. B. (2021). Prostaglandin-associated periorbitopathy syndrome (PAPS): Addressing an unmet clinical need. Seminars in Ophthalmology, 2021,37(4), 447–454

30.Inoue, K., Shiokawa, M., Higa, R. et al. Adverse periocular reactions to five types of prostaglandin analogs. Eye 26, 1465–1472 (2012)

31.Alm, A., Grierson, I., & Shields, M. B. Side effects associated with prostaglandin analog therapy. Survey of ophthalmology, 53 Suppl1,2008, S93–S105.

32.Hu J, Vu JT, Hong B, et al. Uveitis and cystoid macular oedema secondary to topical prostaglandin analogue use in ocular hypertension and open angle glaucoma British Journal of Ophthalmology 2020;104:1040-1044

33.Jedlowski, P. M., & Jedlowski, M. F. Topical ophthalmic beta-blockers are associated with ocular pseudopemphigoid: A pharmacovigilance study of antiglaucoma medications utilising the FDA adverse event reporting system. The Australasian journal of dermatology, 2022, 63(2), 222–227

34.Haga, C., Waller, T., Ahuja, A. S., Farford, B., Dawson, N., & Yin, M. there's danger in the drops: systemic effects of ophthalmic drops used to treat glaucoma. Cureus, 2022,14(1), e20945. 

35.D. Chiseliță.Glaucomul primitiv cu unghi deschis-gînduri și siteze practice;ediția a II-a,Editura Cermi 2020,pag 217-239

36.Alex T Pham  , Chris Bradley  , Kaihua Hou  , Patrick Herbert  , Michael V Boland  , Pradeep Y Ramulu  , Jithin Yohannan  The impact of achieving target intraocular pressure on glaucomatous retinal nerve fiber layer thinning in a treated clinical population Am J Ophthalmol . 2024 Jun: 262:213-221

37.D. Chiseliță.Glaucomul primitiv cu unghi deschis-gînduri și siteze practice-ediția a II-a,Editura Cermi 2020,pag 239-272

38. Douglas J Rhee  , Himani Sancheti  , Adam L Rothman  , Leon Herndon  , Jacob W Brubaker , Thomas Patrianakos, Nathan Radcliffe . Primary Practice Patterns for the Initial Management of Open Angle Glaucoma J Glaucoma. 2024 Sep 1;33(9):671-678

39. Reis, R.; Queiroz, C.F.; Santos, L.C.; Avila, M.P.; Magacho, L. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Clin. Ther. 2006, 28, 552–560

40.Lingham G, Thakur S, SafiS, Gordon I, Evans JR, Keel S. A systematic review of clinical practice guidelines for childhood glaucoma. BMJ OpenOphthalmol. 2022;7(1)

Capitolul 10

  1. Kathuria A, Shamloo K, Jhanji V, Sharma A. Categorization of Marketed Artificial Tear Formulations Based on Their Ingredients: A Rational Approach for Their Use. J Clin Med. 2021 Mar 21;10(6): 1289.
  2. Barabino S, Benitez-Del-Castillo JM, Fuchsluger T, Labetoulle M, Malachkova N, Meloni M, Utheim TP, Rolando M. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification. Eur Rev Med Pharmacol Sci. 2020 Sep;24(17):8642-8652.
  3. Labetoulle M, Benitez-Del-Castillo JM, Barabino S, Herrero Vanrell R, Daull P, Garrigue JS, Rolando M. Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease. Int J Mol Sci. 2022 Feb 23;23(5):2434
  4. Maulvi, Furqan A. et al. Lipid-based eye drop formulations for the management of evaporative dry eyes, Contact Lens and Anterior Eye, Volume 47, Issue 3, 102154
  5. Semp DA, Beeson D, Sheppard AL, Dutta D, Wolffsohn JS. Artificial Tears: A Systematic Review. Clin Optom (Auckl). 2023; 15:9-27  
  6. Aljeaidi M, Keen C, Bell JS, Cooper T, Robson L, Tan ECK. Dry Eyes, Ocular Lubricants, and Use of Systemic Medications Known or Suspected to Cause Dry Eyes in Residents of Aged Care Services. Int J Environ Res Public Health. 2020 Jul 24;17(15):5349. doi: 10.3390/ijerph17155349.
  7. Stapleton F, Velez FG, Lau C, Wolffsohn JS. Dry eye disease in the young: A narrative review. Ocul Surf. 2024 Jan; 31:11-20. doi: 10.1016/j.jtos.2023.12.001. Epub 2023 Dec 7. PMID: 38070708.

Capitolul 11

  1. Colin Chan. Dry eye. A Practical Approach. Springer 2015, 1-19, 85-101
  2. N Mohamed (Registrar) & DP Smit (Consultant). Antiallergic ophtalmic drugs in general practice: which, why and when? Journal of the South African Academy of Family Practice/Primary Care, 2013;55(4):313-318
  3. The spectrum of allergic ocular diseasesJonathan Rodrigues, MD 2021 Ann Allergy Asthma Immunology. 2021 Mar;126(3):240-254.
  4. Andre Farkouth, Peter Frigo Martin Czejka. Systemic side effects of eye drops: a pharmacokinetic perspective. Clinical Ophthalmology 2016:10 2433–2441
  5. Robert S. Duszak, OD, FAAO⁎, Emily R. Carr, OD, FAAO, Rajni K. Acharya, OD, FAAO, and Lisa V. Stottlemyer, OD, FAAO. Capitol 35. Side effects of drugs used in ocular treatment. Side Effects of Drugs Annual, Elsevier, 2022, volum 44, pag 483-493
  6. Kimchi, Nofar; Bielory, Leonard. The allergic eye: recommendations about pharmacotherapy and recent therapeutic agents, Kimchi, Nofar; Bielory, Leonard. The allergic eye: recommendations about pharmacotherapy and recent therapeutic agents, Curr Opin Allergy Clin Immunol 2020, 20:414–420 DOI:10.1097/ACI.0000000000000669
  7. Hadas Ben-Elia, Abraham Solomona. Topical antihistamines, mast cell stabilizers, and dual-action agents in ocular allergy: current trends, Current Opinion in Allergy and Clinical Immunology 18(5):p 411-416, October 2018. | DOI: 10.1097/ACI.00000000000004732018
  8. Leonard Bielory, Ocular Allergy Treatments Clin Rev Allergy Immunol. 2001 Apr;20(2): 201-13.doi: 10.1385/CRIAI:20:2:201.
  9. Andreea Leonardi, Diana Silva. Management of ocular allergy. Allergy, 2019 Sep;74(9): 1611-1630.doi: 10.1111/all.13786.
  10. Adam J. Cohen Michael Mercandetti. The lacrimal System, , Diagnosis, Management, and Surgery, Second EditionSpringer, 2015
  11. Anat Galor. Dry Eye Disease, Elsevier 2023

Capitolul 12

  1. Miller J.W., Adamis A.P., Shima D.T., D'Amore P.A., Moulton R.S., O'Reilly M.S., Folkman J., Dvorak H.F., Brown L.F., Berse B., Yeo T.K., Yeo K.T. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994 ;145 :574–584.
  2. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E., Nguyen H.V Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994 ;331 :1480–1487.
  3. Campochiaro PA. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. 2015; 49:67–81
  4. Chalam KV, Brar VS, Murthy RK. Human ciliary epithelium as a source of synthesis and secretion of vascular endothelial growth factor in neovascular glaucoma. JAMA Ophthalmol.2014;132(11):1350–4
  5. Kaur C, Foulds WS, Ling E-A. Hypoxia-ischemia and retinal ganglion cell damage. Clin Ophthalmol. 2008;2(4):879–89
  6. Shin, Y. J, Choi, J. S. et al. (2010). "Induction of vascular endothelial growth factor receptor-3 mRNA in glial cells following focal cerebral ischemia in rats". J Neuroimmunol. 229 (1–2): 81–90
  7. McColm JR, Geisen P, Hartnett ME. VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. Mol Vis 2004; 10: 512-20
  8. Gordon M.S., Margolin K., Talpaz M., Sledge G.W., Jr, Holmgren E., Benjamin R., Stalter S., Shak S., Adelman D. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001; 19:843–850
  9. Michels S., Rosenfeld P.J., Puliafito C.A., Marcus E.N., Venkatraman A.S. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005 ;112 :1035–1047
  10. Rosenfeld P.J., Moshfeghi A.A., Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005 ;36 :331–335
  11. Branisteanu D, Moraru A. Rezultatele tratamentului intravitrean cu bevacizumab în neovascularizaţia subretiniană din miopia forte [The results of intravitreal bevacizumab in high myopic subretinal neovascularisation]. Oftalmologia. 2013 ;57(3):58-65. Romanian. PMID: 24701816.
  12. Dimofte D, Danielescu C, Chiseliţă D. Tratamentul cu bevacizumab în forma exudativă a DMLV [Treatment with bevacizumab in exudative age-related macular degeneration]. Oftalmologia. 2010 ;54(2) :116-22. Romanian. PMID : 20827921.
  13. Taban C, Merticariu A, Melcioiu L, Oprescu A, Ionescu R, Iacob A, Pienaru M, Desliu D, Balta F. Choroidal neovascular membrane in Best juvenile dystrophy treated with intravitreal bevacizumab. Oftalmologia. 2013;57(3):47-51, 42-6. English, Romanian. PMID: 24701814.
  14. Brănişteanu D, Moraru A. Rezultatele tratamentului cu bevacizumab intravitrean în neovascularizaţia subretiniana din striurile angioide [The results of intravitreal bevacizumab in subretinal neovascularisation in angioid streaks]. Oftalmologia. 2014 ;58(1) :48-55. Romanian.
  15. Călugăru D, Călugăru M, Țălu Ș. Bevacizumab in the treatment of acute central/hemicentral retinal vein occlusions. Rom J Ophthalmol. 2016 Jul-Sep ;60(3) :145-152
  16. Nicoară SD, Nascutzy C, Cristian C, Irimescu I, Ștefănuț AC, Zaharie G, Drugan T. Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity. J Ophthalmol. 2015; 2015:102582
  17. Cormos D. Complications of combined retinal and retinal pigment epithelium hamartoma involving the optic disc in a child, treated with Avastin - a review of the literature and case presentation. Rom J Ophthalmol. 2015 Oct-Dec;59(4):255-262
  18. Dascalu AM, Popa-Cherecheanu A, Popa-Cherecheanu M, Nica A, Serban D. "Off-label" use of intravitreal bevacizumab in non-ischemic macular edema secondary to retinal vein obstructions. Rom J Ophthalmol. 2016 Apr-Jun;60(2):90-95
  19. Stanca HT, Stanca S, Tabacaru B, Boruga M, Balta F. Bevacizumab in Wet AMD treatment: A tribute to the thirteen years of experience from the beginning of the anti-VEGF era in Romania. Exp Ther Med. 2019 Dec;18(6):4993-5000
  20. ANM data ultimei accesari la 11 ianuarie 2025
  21. EMA data ultimei accesari la 3 ianuarie 2025
  22. Gragoudas E.S., Adamis A.P., Cunningham E.T., Jr, Feinsod M., Guyer D.R., VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004 ;351 :2805–2816
  23. EMA, data ultimei accesari la 3 ianuarie 2025
  24. Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, et al. (2012). "A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard". PLOS ONE. 7 (8) : e42701.
  25. Jiang S, Park C, Barner JC (June 2014). "Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab". Journal of Clinical Pharmacy and Therapeutics. 39 (3) : 234–239
  26. CATT Research Group. Martin D.F., Maguire M.G., Ying G.S., Grunwald J.E., Fine S.L., Jaffe G.J. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 ;364 :1897–1908
  27. Hutton D, Newman-Casey PA, Tavag M, Zacks D, Stein J (June 2014). "Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period". Health Affairs. 33 (6) : 931–939
  28. EMA data ultimei accesari la 5 ianuarie 2025
  29. EMA data ultimei accesari la 5 ianuarie 2025
  30. EMA data ultimei accesari la 3 ianuarie 2025
  31. EMA data ultimei accesari la 5 ianuarie 2025
  32. EMA data ultimei accesari la 5 ianuarie 2025
  33. Varma R, Bressler NM, Doan QV, et al. Visual impairment and blindness avoided with ranibizumab in Hispanic and non-Hispanic whites with diabetic macular edema in the United States. Ophthalmology. 2015; 122:982–9.
  34. Tracey ML, McHugh SM, Fitzgerald AP, Buckley CM, Canavan RJ, Kearney PM. Trends in blindness due to diabetic retinopathy among adults aged 18–69 years over a decade in Ireland. Diabetes Res Clin Pract. 2016; 121:1–8.
  35. EMA data ultimei accesari la 3 ianuarie 2025
  36. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, Jonas J, Larsen M, Tadayoni R, Loewenstein A. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185-222
  37. EMA data ultimei accesari la 3 ianuarie 2025
  38. EMA data ultimei accesari la 3 ianuarie 2025
  39. EMA data ultimei accesari la 25 ianuarie 2025
  40. EMA data ultimei accesari la 25 ianuarie 2025
  41. EMA data ultimei accesari la 3 ianuarie 2025
  42. EMA data ultimei accesari la 3 ianuarie 2025
  43. FDA data ultimei accesari la 5 ianuarie 2025
  44. Grzybowski A, Told R, Sacu S, Bandello F, Moisseiev E, Loewenstein A, Schmidt-Erfurth U; Euretina Board. 2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations. Ophthalmologica. 2018;239(4):181-193.
  45. Veritti, D., Sarao, V., Chhablani, J. et al. The ideal intravitreal injection setting: office, ambulatory surgery room or operating theatre? A narrative review and international survey. Graefes Arch Clin Exp Ophthalmol 261, 3299–3306 (2023).

Capitolul 13

  1. Nathan, Paul et al. “Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.” The New England journal of medicine vol. 385,13 (2021): 1196-1206. doi:10.1056/NEJMoa2103485
  2. Behl, Tapan et al. “Exploring the multifocal role of phytochemicals as immunomodulators.” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 133 (2021
  3. Lansiaux, Amélie. “Les antimétabolites” [Antimetabolites]. Bulletin du cancer vol. 98,11 (2011): 1263-74. doi:10.1684/bdc.2011.1476
  4. Das, Shinjita et al. “T-cell inhibitors: a bench-to-bedside review.” Dermatitis: contact, atopic, occupational, drug vol. 23,5 (2012): 195-202. doi:10.1097/DER.0b013e31826e43ed
  5. Bardal Stan K., Waechter Jason E, Martin Douglas S. Applied Pharmacology, Elsevier Health Sciences, 2011
  6. Scheinfeld, N. “A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab.” The Journal of dermatological treatment vol. 15,5 (2004): 280-94. doi:10.1080/09546630410017275
  7. Arend, W P. “Interleukin-1 receptor antagonist.” Advances in immunology vol. 54 (1993): 167-227. doi:10.1016/s0065-2776(08)60535-0
  8. Tanaka, Toshio et al. “IL-6 in inflammation, immunity, and disease.” Cold Spring Harbor perspectives in biology vol. 6,10 a016295. 4 Sep. 2014, doi:10.1101/cshperspect. a016295
  9. Khalilzadeh, Mina et al. “A comprehensive insight into the anti-inflammatory properties of dapsone.” Naunyn-Schmiedeberg's archives of pharmacology vol. 395,12 (2022): 1509-1523.
  10. Leung, Ying Ying et al. “Colchicine--Update on mechanisms of action and therapeutic uses.” Seminars in arthritis and rheumatism vol. 45,3 (2015): 341-50. doi: 10.1016/j.semarthrit.2015.06.013
  11. Bayry, J et al. “Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases.” Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine vol. 10,3 (2003): 165-9. doi:10.1016/s1246-7820(03)00035-1
  12. Thomas, Howard et al. “Mechanisms of action of interferon and nucleoside analogues.” Journal of hepatology vol. 39 Suppl 1 (2003): S93-8. doi:10.1016/s0168-8278(03)00207-1
  13. Kieseier, Bernd C. “The mechanism of action of interferon-β in relapsing multiple sclerosis.” CNS drugs vol. 25,6 (2011): 491-502. doi:10.2165/11591110-000000000-00000
  14. Bonelli, Michael, and Clemens Scheinecker. “How does abatacept really work in rheumatoid arthritis?” Current opinion in rheumatology vol. 30,3 (2018): 295-300.
  15. Anglade, Eddy et al. “A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin.” Clinical ophthalmology (Auckland, N.Z.) vol. 2,4 (2008): 693-702.
  16. Foster, C Stephen et al. “The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management.” Survey of ophthalmology vol. 61,1 (2016): 1-17.
  17. van der Horst-Bruinsma, Irene E et al. “Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study.” Therapeutic advances in musculoskeletal disease vol. 13 1759720X211003803. 29 Mar. 2021,
  18. William, Mridula et al. “Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis.” Journal of ophthalmic inflammation and infection vol. 2,4 (2012): 231-3.
  19. Cordero-Coma, Miguel et al. “Golimumab for uveitis.” Ophthalmology vol. 118,9 (2011): 1892.e3-4. doi: 10.1016/j.ophtha.2011.05.019
  20. Rituxan FDA, accessed on 18th Dec 2024
  21. Teoh, S C B et al. “Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome.” The British journal of ophthalmology vol. 91,2 (2007): 263-4. doi:10.1136/bjo.2006.0101477
  22. Fabiani, Claudia et al. “Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.” Clinical rheumatology vol. 36,1 (2017): 191-197. doi:10.1007/s10067-016-3506-4
  23. Wroblewski, Keith et al. “Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease.” Canadian journal of ophthalmology. Journal canadien d'ophtalmologie vol. 46,4 (2011): 322-8. doi: 10.1016/j.jcjo.2011.06.008
  24. Mesquida, Marina et al. “Twenty-four-month follow-up of tocilizumab therapy for refractory uveitis-related macular edema.” Retina (Philadelphia, Pa.) vol. 38,7 (2018): 1361-1370.
  25. DAPSONE, accessed on 21st Dec 2024
  26. COLCRYS (colchicine) , accessed on 21st Dec 2024
  27. Brunton LL, Knollmann BC, Hilal-Dandan R, editors. “Goodman & Gilman’s the pharmacological basis of therapeutics”. Thirteenth edition. New York: McGraw Hill Medical; 2018.
  28. FDA label of PEGASYS® (peginterferon alfa-2a) accessed on 2nd Dec 2024
  29. Menon, Vimla et al. “Management of optic neuritis.” Indian journal of ophthalmology vol. 59,2 (2011): 117-22. doi:10.4103/0301-4738.77020
  30. Tappeiner, Christoph et al. “Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis.” The Journal of rheumatology vol. 42,4 (2015): 706-11. doi:10.3899/jrheum.140410
  31. FDA label of NEORAL® Soft Gelatin Capsules (cyclosporine capsules, USP) MODIFIED, accessed on 2nd Dec. 2024

Capitolul 14

  1. Joobin Khadamy, Nutrients for Eye Health and Disease Management
  2. Castro-Castaneda, Carlos Rodrigo et al. “Nutraceuticals: A Promising Therapeutic Approach in Ophthalmology.” Nutrients vol. 14,23 5014. 25 Nov. 2022, doi:10.3390/nu14235014
  3. Siddiqui, Rafat A, and Mohammed H Moghadasian. “Nutraceuticals and Nutrition Supplements: Challenges and Opportunities.” Nutrients vol. 12,6 1593. 29 May. 2020, doi:10.3390/nu12061593
  4. Amol Ganvir, Leo A. Kim, Nimesh Patel, Oxidative stress in Ophthalmology, accesat 17.12.2024
  5. Zehiroglu, Cuma, and Sevim Beyza Ozturk Sarikaya. “The importance of antioxidants and place in today's scientific and technological studies.” Journal of food science and technology vol. 56,11 (2019): 4757-4774. doi:10.1007/s13197-019-03952-x
  6. Ruxandra Pirvulescu, Raluca Iancu, Sinziana Istrate, Aida Geamanu, Alexandra Vrapciu, Alina Popa Cherecheanu - Neuroprotecția în glaucom – între necesitate și incertitudine, Oftalmologia clinica – vol V sub redactia. Danut Costin, ISBN 976-606-13-4577-9, Editura Pim, Iasi, 2022
  7. Labkovich, Margarita et al. “Ginkgo Biloba Extract in Ophthalmic and Systemic Disease, With a Focus on Normal-Tension Glaucoma.” Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) vol. 9,3 (2020): 215-225. doi:10.1097/APO.0000000000000279
  8. Quaranta, Luciano et al. “Ginkgo biloba extract improves visual field damage in some patients affected by normal-tension glaucoma.” Investigative ophthalmology & visual science vol. 55,4 2417. 15 Apr. 2014, doi:10.1167/iovs.14-13942
  9. Lee, Jeongmin et al. “Effect of Ginkgo biloba extract on visual field progression in normal tension glaucoma Journal of glaucoma vol. 22,9 (2013): 780-4. doi:10.1097/IJG.0b013e3182595075
  10. Jerome Ndudi Asiweet al. Inhibition of oxido-inflammatory and apoptotic pathway is involved in the protective effect of Ginkgo biloba supplement in cyclosporine-A induced vascular dysfunction in Wistar rat, Pharm. Research - Modern Chinese Medicine, Volume 7/2023, ISSN 2667-1425ț
  11. Terminology and guidelines for Glaucoma, 5th edition,
  12. Drugs.com, accesat 18.12.2024
  13. Gandolfi, Stefano et al. “Cytidine 5'-Diphosphocholine (Citicoline): Evidence for a Neuroprotective Role in Glaucoma.” Nutrients vol. 12,3 793. 18 Mar. 2020, doi:10.3390/nu12030793
  14. Alexander G. Schauss PhD, Eri Nakazaki PhD, in Textbook of Natural Medicine (Fifth Edition), vol. 1, 2020
  15. WebMD, accesat 18.12.2024
  16. Parisi, Vincenzo et al. “Treatment with citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma.” Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie vol. 253,8 (2015): 1327-40. doi:10.1007/s00417-015-3044-9
  17. Ahmad, Syed S. “Coenzyme Q and its role in glaucoma.” Saudi journal of ophthalmology: official journal of the Saudi Ophthalmological Society vol. 34,1 45-49. 22 Nov. 2020, doi:10.4103/1319-4534.301299
  18. NEI.NIH.GOV accesat 19.12.2024
  19. Choo, Priscilla Peixi et al. “Review of Evidence for the Usage of Antioxidants for Eye Aging.” BioMed research international vol. 2022 5810373. 3 Oct. 2022, doi:10.1155/2022/5810373
  20. Rasmussen, Helen M, and Elizabeth J Johnson. “Nutrients for the aging eye.” Clinical interventions in aging vol. 8 (2013): 741-8. doi:10.2147/CIA.S45399
  21. Giannaccare, Giuseppe et al. “Clinical Applications of Astaxanthin in the Treatment of Ocular Diseases: Emerging Insights.” Marine drugs vol. 18,5 239. 1 May. 2020, doi:10.3390/md18050239
  22. Abu-Amero, Khaled K et al. “Resveratrol and Ophthalmic Diseases.” Nutrients vol. 8,4 200. 5 Apr. 2016, doi:10.3390/nu8040200
  23. Bryl, Anna et al. “The Role of Resveratrol in Eye Diseases-A Review of the Literature.” Nutrients vol. 14,14 2974. 20 Jul. 2022, doi:10.3390/nu14142974
  24. Duncan, Andrew et al. “The risk of copper deficiency in patients prescribed zinc supplements.” Journal of clinical pathology vol. 68,9 (2015): 723-5. doi:10.1136/jclinpath-2014-202837
  25. Medscape accesat 21.12.2025
  26. ODS.NIH.GOV, accesat 21.12.2025
  27. Reins, Rose Y, and Alison M McDermott. “Vitamin D: Implications for ocular disease and therapeutic potential.” Experimental eye research vol. 134 (2015): 101-10. doi: 10.1016/j.exer.2015.02.019
  28. Gorimanipalli, Bhavya et al. “Vitamin D and eye: Current evidence and practice guidelines.” Indian journal of ophthalmology vol. 71,4 (2023): 1127-1134. doi: 10.4103/IJO.IJO_3174_22
  29. Latib, Fazira et al. “The use of vitamin E in ocular health: Bridging omics approaches with Tocopherol and Tocotrienol in the management of glaucoma.” Food chemistry. Molecular sciences vol. 9 100224. 24 Sep. 2024, doi: 10.1016/j.fochms.2024.100224
  30. Zhang, Wen-Hua et al. “Neuroprotective role of epigallocatechin-3-gallate in acute glaucoma via the nuclear factor-κB signalling pathway.” Experimental and therapeutic medicine vol. 22,5 (2021): 1235. doi:10.3892/etm.2021.10669

Capitolul 15

  1. Kugler, E.C., Greenwood, J., Macdonald, R.B., 2021. The "neuro-glial-vascular" unit: the role of glia in neurovascular unit formation and dysfunction. Front. Cell Dev. Biol. 9, 732820.
  2. Alarcon-Martinez L, Shiga Y, Villafranca-Baughman D, Cueva Vargas JL, Vidal Paredes IA, Quintero H, Fortune B, Danesh-Meyer H, Di Polo A. Neurovascular dysfunction in glaucoma. Prog Retin Eye Res. 2023 Nov; 97:101217. doi: 10.1016/j.preteyeres.2023.101217. Epub 2023 Sep 30. PMID: 37778617.
  3. Senée P, Krafft L, Farias DC, Thouvenin O, Atlan M, Paques M, Meimon S, Mecê P; Measuring the retinal neurovascular coupling in the human eye at a high spatial and temporal resolution. Invest. Ophthalmol. Vis. Sci. 2024;65(7):1513.
  4. Wareham, L.K., Calkins, D.J., 2020. The neurovascular unit in glaucomatous neurodegeneration. Front. Cell Dev. Biol. 8, 452.
  5. Sung, K.R., Lee, S., Park, S.B., Choi, J., Kim, S.T., Yun, S.C., Kang, S.Y., Cho, J.W., Kook, M.S., 2009. Twenty-four-hour ocular perfusion pressure fluctuation and risk of normal-tension glaucoma progression. Invest. Ophthalmol. Vis. Sci. 50, 5266–5274.
  6. Hayreh, S.S. Blood flow in the optic nerve head and factors that may influence it. Prog. Retin. Eye Res. 2001, 20, 595–624.
  7. Zhang, X.; Zhou, X.; Zhao, Y.; Yang, X.; Zhou, D.; Chen, B.; Duan, X. Effects of tafluprost on ocular blood flow. Ophthalmol. Ther. 2022, 11, 1991–2003.
  8. Seibold, L.K.; DeWitt, P.E.; Kroehl, M.E.; Kahook, M.Y. The 24-hour effects of brinzolamide/brimonidine fixed combination and timolol on intraocular pressure and ocular perfusion pressure. J. Ocul. Pharmacol. Ther. 2017, 33, 161–169. 
  9. Samaha, D.; Diaconu, V.; Bouchard, J.F.; Desalliers, C.; Dupont, A. Effect of latanoprostene bunod on optic nerve head blood flow. Optom. Vis. Sci. 2022, 99, 172–176.
  10. Virani S, Rewri P. A Narrative Review of Pharmacotherapy of Glaucoma. Future Pharmacology. 2024; 4(2):395-419.
  11. Reboussin, É., Bastelica, P., Benmessabih, I. et al. Evaluation of Rho kinase inhibitor effects on neuroprotection and neuroinflammation in an ex-vivo retinal explant model.acta neuropathol commun 12, 150 (2024). 
  12. Wang LH, Huang CH, Lin IC. Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Technologies. Pharmaceuticals (Basel). 2024 Sep 25;17(10):1261.
  13. Namekata, K.; Noro, T.; Nishijima, E.; Sotozono, A.; Guo, X.; Harada, C.; Shinozaki, Y.; Mitamura, Y.; Nakano, T.; Harada, T. Drug combination of topical ripasudil and brimonidine enhances neuroprotection in a mouse model of optic nerve injury. J. Pharmacol. Sci. 2024, 154, 326–333.
  14. Islam S, Spry C. Prostaglandin Analogues for Ophthalmic Use: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Feb 18. 
  15. Martínez A, Sánchez-Salorio M. A comparison of the long-term effects of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5%, on retrobulbar hemodynamics and intraocular pressure in open-angle glaucoma patients. J Ocul Pharmacol Ther. 2009 Jun;25(3):239-48.
  16. Parisi V, Coppola G, Ziccardi L, Gallinaro G, Falsini B. Cytidine-5'-diphosphocholine (Citicoline): a pilot study in patients with non-arteritic ischaemic optic neuropathy. Eur J Neurol. 2008 May;15(5):465-74. 
  17. Vishwaraj CR, Kavitha S, Venkatesh R, Shukla AG, Chandran P, Tripathi S. Neuroprotection in glaucoma. Indian J Ophthalmol. 2022 Feb;70(2):380-385. 
  18. EA. Functional hyperemia and mechanisms of neurovascular coupling in the retinal vasculature. J Cereb Blood Flow Metab. 2013; 33:1685–1695.
  19. Simó R, Simó-Servat O, Bogdanov P, Hernández C. Diabetic Retinopathy: Role of Neurodegeneration and Therapeutic Perspectives. Asia Pac J Ophthalmol (Phila). 2022 Mar-Apr 01;11(2):160-167. 

Capitolul 16

1.Kera N, Ribeiro Koch C, Rodrigues de Santhiago M, Farnari L, Caramelli B – Anticoagulant and antiplatelet drugs during cataract surgery – Arch Bras Ophthalmol 2018;81(4) 348-353

2.Chen AF, He X, Nirvan RS, Sridher J, Kuriyan AE – Perioperative Management of Anticoagulants in Ocular Surgery Int Ophthalmol Clin 2020; 60(3) 3-15

3.Dornbas D, Nimgee SM – Reversal of Systemic Anticoagulant and Antiplatelet Therapeutics – Nerosurg Clin N Am 2018; 29 (4): 537-545

4.Clinical Excellence Commission 2023Direct Anticoagulants (DOAC) Guidelines, Octoner 2023, Sydney, pg 14

5. Clinical Excellence Commission 2023Direct Anticoagulants (DOAC) Guidelines, Octoner 2023, Sydney, pg 10-11

6.Fraser SG, Adam W – Interventions for acute nonarteritic central retinal artery occlusion Cochrane Database Syst Rev 2009; 1(1) CD001989

7.Schumacher M, Schmidt D, Jurklers B et al EAGLE - European Assessment Group for Lysis in the Eye - Central retinal artery occlusion: local intraarterial fibrinolisis versus conservative treatment, a multicenter randomized trial Ophthalmology 2010; 7 (&) : 1367-1375

8.Hacke W, Kaste M, Bluhmen E et al ECASS Investigators Trombolysis with alteplase to 4,5 hour after acute ischemic stroke N Engl J Med 2008; 395 (13) 1317-1329

9.Schrag M, Youn T, Schindler J, Hischner H Greer D – Intravenous fibrinolytic therapy in central retinal artery occlusion: a patient level metaanalysis JAMA Neurol 2015; 72:1148-1154

10.Van Zeeburg JT, Van Mars JC Literature review of recombinant tissue plasminogen activator used for reccurent macular hemorrhage displacement in age-related macular degeneration Ophthalmology 2012; 229(1): 1-14

11.Avery RL, Fekrat S, Waekins BS, Bressler NM Natural history of subfoveal subretinal hemorrhage in age related macular degeneration Retina 1996; 16(3) 183-189

12.Ianetta D, de Maria N, Bolleto E, Mastrofilippo V, Moramorca A, Fontana L – Subretinal Injection of Recombinant Tissue Plasminogen Activatorand Gas Tamponade to Displace Acute Subnacular Hemorrhage Secondary to Age-Related Macular Degeneration Clinical Ophthalmology 2021; 15: 3649-3659

13.Shone JH, TuewellK, Dimonaco Sklearmach U, Aringer M, Blockmans D, Bronwer E, Cid MC, Dagupto A Rach J Trial of Tolicizumab in Giant Cell Arteritis N Engl J Med 2017; 377: 317-328

14.Miller NR, Arnold AC Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischemic optic neuropathy Eye 2015; 29: 65-79

15.Bialer OY, Stiebel – Kalish H Evaluation and menagement of nonarteritic anterior ischemic optic neuropathy A national survey Graephe’s Arch Clin Exp Ophthalmol 2024: 262: 3323-3330

16.Lantos K, Domotor ZR, Farkas N, Kiss S, Stelkas S, Garami A, Varga G Lujbo I, Kanaan R, Heghy P et al – Efficacy of Treatment in Non Arteritic Ischemic Optic Neuropathy Systematic Review and Meta-Analysis- Int J Envirron Res Public Health 2022, 19 , 2718

17. Thomas GM, Kiew SY, Singh P, Dimitriev P, Thomas AD, Fekrat S – Central Retinal Vein Occlusion : The Effect of Antiplatelet and Anticoagulant Agents J Vitreoretinal Dis 2021; Jul 30 6 (2) 97-103

18. Hayreth SS, Podhayski PA, Zimmerman B – Central and Hemicentral Retinal Vein Occlusion – Role of Antiplatelet Aggregation Agents and anticoagulants Ophthalmology, 2011, vol 118 issue 8, 1603-1611

19. Laza-Lagner A, Maxwel J, Ageno W, Kovacs MJ – Low molecular weight heparin for the treatment of retinal vein occlusion: a Systematic Review and Meta-analysis of randomized trials: Haematologica 2010, vol 95; 9-13

Capitolul 17 I.

  1. Al Bayyat G, Arreaza-Kaufman D, Venkateswaran N, Galor A, Karp CL. Update on pharmacotherapy for ocular surface squamous neoplasia. Eye Vis (Lond). 2019 Aug 12; 6:24. 
  2. Yeoh, C.H.Y.; Lee, J.J.R.; Lim, B.X.H.; Sundar, G.; Mehta, J.S.; Chan, A.S.Y.; Lim, D.K.A.; Watson, S.L.; Honavar, S.G.; Manotosh, R.; et al. The Management of Ocular Surface Squamous Neoplasia (OSSN). Int. J. Mol. Sci. 2023, 24, 713. 
  3. Adam Wylegala, Wathanee Sripawadkul, Mike Zein, Osmel P. Alvarez, Ghada Al Bayyat, Anat Galor. Topical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: Long-term follow-up study. The Ocular Surface, Volume 27, 2023, Pages 67-74, ISSN 1542-0124, 
  4. Basti S, Macsai MS. Ocular surface squamous neoplasia: a review. Cornea. 2003 Oct;22(7):687-704. doi: 10.1097/00003226-200310000-00015. PMID: 14508267.
  5. Casale J, Patel P. Fluorouracil. [Updated 2024 Feb 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan
  6. Ramasubramanian, A. (2019). Ocular oncology. Springer. Pages 61-75, ISBN 978-981-13-7538-5
  7. Parrozzani R, Lazzarini D, Alemany-Rubio E, Urban F, Midena E. Topical 1% 5-fluorouracil in ocular surface squamous neoplasia: a long-term safety study. Br J Ophthalmol. 2011 Mar;95(3):355-9
  8. Joag MG, Sise A, Murillo JC, Sayed-Ahmed IO, Wong JR, Mercado C. Topical 5-Fluorouracil 1% as Primary Treatment for Ocular Surface Squamous Neoplasia. Ophthalmology. 2016 Jul;123(7):1442-8. 
  9. Pinnita Prabhasawat, Nattaporn Tesavibul, Kanjana Leelapatranura, Teeranit Phonjan. Efficacy of Subconjunctival 5-Fluorouracil and Triamcinolone Injection in Impending Recurrent Pterygium. Ophthalmology,Volume 113, Issue 7, 2006, Pages 1102-1109, ISSN 0161-6420,.
  10. B. W.H. Lee, A S. Sidhu, I. C. Francis, M. T. Coroneo. 5-Fluorouracil in primary, impending recurrent and recurrent pterygium: Systematic review of the efficacy and safety of a surgical adjuvant and intralesional antimetabolite. The Ocular Surface. Volume 26, 2022, Pages 128-141, ISSN 1542-0124 
  11. Alvarez OP, Zein M, Serrano A, Galor A, Karp CL. Punctal and Canalicular Stenosis Following Topical 1% 5-Fluorouracil Eye Drop Therapy for Ocular Surface Squamous Neoplasia. Cornea. 2024 Nov 1;43(11):1418-1422. 
  12. Sinawe H, Casadesus D. Mitomycin. [Updated 2023 Jul 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. 
  13. Martins TG, Costa AL, Alves MR, Chammas R, Schor P. Mitomycin C in pterygium treatment. Int J Ophthalmol. 2016 Mar 18;9(3):465-8. 
  14. Donnenfeld ED, Perry HD, Fromer S, Doshi S, Solomon R, Biser S. Subconjunctival mitomycin C as adjunctive therapy before pterygium excision. Ophthalmology. 2003 May;110(5):1012-6
  15. Kozma, K., Dömötör, Z.R., Csutak, A. et al. Topical pharmacotherapy for ocular surface squamous neoplasia: systematic review and meta-analysis. Sci Rep 12, 14221 (2022). 
  16. Sayed-Ahmed IO, Palioura S, Galor A, Karp CL. Diagnosis and Medical Management of Ocular Surface Squamous Neoplasia. Expert Rev Ophthalmol. 2017;12(1):11-19. 
  17. Lindquist TP, Lee WB. Mitomycin C-associated scleral stromalysis after pterygium surgery. Cornea. 2015 Apr;34(4):398-401. 

Capitolul 17 II.

  1. McDonnell, George, and A. D. Russell. “Antiseptics and Disinfectants: Activity, Action, and Resistance.” Clinical Microbiology Reviews, vol. 12, no. 1, Jan. 1999, pp. 147–79.
  2. Lopalco, Antonella et al. “Boric Acid, a Lewis Acid with Unique and Unusual Properties: Formulation Implications.” Journal of Pharmaceutical Sciences, vol. 109, no. 8, 2020, pp. 2375–86.
  3. Barry, Peter et al. “Prophylaxis of Postoperative Endophthalmitis Following Cataract Surgery: Results of the ESCRS Multicenter Study and Identification of Risk Factors.” Journal of Cataract and Refractive Surgery, vol. 33, 2007, pp. 978–88.
  4. Peyman, A., M. Hosseini, and T. Narimani. “Comparison of the Effects of Povidone-Iodine 5%, Polyhexamethylene Biguanide, and Chlorhexidine as a Preoperative Antiseptic in Endophthalmitis Prophylaxis in Patients Undergoing Phacoemulsification Cataract Surgery.” Advances in Biomedical Research, vol. 9, 22 Apr. 2020, p. 15.
  5. Papa, Vincenzo et al. “Safety and Tolerability of Topical Polyhexamethylene Biguanide: A Randomised Clinical Trial in Healthy Adult Volunteers.” Brit Jour of Ophthalmology, vol. 106, 2022, pp. 190–6.

Capitolul 17 III.

  1. Scott AB, Honeychurch D, Brin MF. Early development history of Botox (onabotulinumtoxinA). Medicine (Baltimore). 2023 Jul 1;102(S1):e32371.
  2. Başar E, Arıcı C. Use of Botulinum Neurotoxin in Ophthalmology. Turk J Ophthalmol. 2016 Dec;46(6):282-290. doi: 10.4274/tjo.57701. Epub 2016 Dec 1. PMID: 28050326; PMCID: PMC5177786.
  3. Dutton JJ, Fowler AM. Botulinum toxin in ophthalmology. Surv Ophthalmol. 2007 Jan-Feb;52(1):13-31. doi: 10.1016/j.survophthal.2006.10.003. PMID: 17212988.
  4. Marsh IB. Botulinum toxin and the eye. Hosp Med. 2003 Aug;64(8):464-7.
  5. Wabbels B. Botulinumtoxintherapie – neue Entwicklungen in der Augenheilkunde [Botulinum Toxin - New Developments in Ophthalmology]. Klin Monbl Augenheilkd. 2018 Jun;235(6):721-724. German.
  6. Mittal R, Patel S, Galor A. Alternative therapies for dry eye disease. Curr Opin Ophthalmol. 2021 Jul 1;32(4):348-361.
  7. Chua CN, Quhill F, Jones E, et al: Treatment of aberrant facial nerve regeneration with botulinum toxin A. Orbit 23: 213--8, 2004
  8. Leszczynska A, Nowicka D, Pillunat LE, Szepietowski JC. Five decades of the use of botulinum toxin in ophthalmology. Indian J Ophthalmol. 2024 Jun 1;72(6):789-795.
  9. Dutton JJ: Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects. Surv Ophthalmol 41:51-65, 1996
  10. Carruthers J, Fagien S, Matarasso SL; Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. Plast Reconstr Surg. 2004 Nov;114(6 Suppl):1S-22S.
  11. Borba A, Matayoshi S, Rodrigues M. Avoiding Complications on the Upper Face Treatment With Botulinum Toxin: A Practical Guide. Aesthetic Plast Surg. 2022 Feb;46(1):385-394.

Capitolul 18

  1. McKiever, M.; Frey, H.; Costantine, M.M. Challenges in Conducting Clinical Research Studies in Pregnant Women. J Pharmacokinet. Pharmacodyn. 2020, 47, 287–293.
  2. Syme, M.R.; Paxton, J.W.; Keelan, J.A. Drug Transfer and Metabolism by the Human Placenta. Clin Pharmacokinet. 2004, 43, 487–514.
  3. Harris, J.B.; Holmes, A.P.; Eiland, L.S. The Influence of the Food and Drug Administration Pregnancy and Lactation Labeling Rule on Drug Information Resources. Ann. Pharmacother. 2021, 55, 459–465.
  4. Ahmed, S.; Amin, M.M.; Sayed, S. Ocular Drug Delivery: A Comprehensive Review. AAPS PharmSciTech 2023, 24, 66.
  5. Ghate, D.; Edelhauser, H.F. Ocular Drug Delivery. Expert Opin. Drug Deliv. 2006, 3, 275–287.
  6. Schopf, L.R.; Popov, A.M.; Enlow, et al. Topical Ocular Drug Delivery to the Back of the Eye by Mucus-Penetrating Particles. Transl. Vis. Sci. Technol. 2015, 4, 11
  7. Varela-Fernández, R.; Díaz-Tomé, V.; Luaces-Rodríguez, A. et al. Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations. Pharmaceutics 2020, 12, 269
  8. Shinomiya, K.; Kajima, M.; Tajika, et al Renal Failure Caused by Eyedrops Containing Phenylephrine in a Case of ROP. J. Med. Investig. 2003, 50, 203–206
  9. Razeghinejad, M.R.; Tania Tai, T.Y.; Fudemberg, S.J.; Katz, L.J. Pregnancy and glaucoma. Surv. Ophthalmol. 2011, 56, 324–335
  10. Ness, T., Paulus, W. Ophthalmika während Schwangerschaft und Stillzeit.Ophthalmologe 109,221–228 (2012).
  11. American Academy of Pediatrics on Drugs, 1994; The transfer of drugs and other chemicals into human mik. Pediatrics 93:137-150.
  12. Demarinis, G.; Tatti, F.; Taloni, A et al. Treatments for Ocular Diseases in Pregnancy and Breastfeeding: A Narrative Review. Pharmaceuticals 2023, 16, 1433.
  13. Oxford Handbook of Ophthalmology (Oxford Medical Handbooks), Ed. 4
  14. Asociația Americană de Pediatrie, Ghid de Practica 2022-2023
  15. Ghidul OMS, 2023
  16. AAAO 
  17. Yefet, E.; Schwartz, N.; Chazan et al The Safety of Quinolones and Fluoroquinolones in Pregnancy: A Meta-Analysis. BJOG 2018, 125, 1069–1076
  18. Reali, A.; Ximenes, A.; Cuzzolin, L.; Fanos, V. Antibiotic Therapy in Pregnancy and Lactation. J. Chemother. 2005, 17, 123–130.
  19. Sheehy O, Santos F, Ferreira E, Berard A. The use of metronidazole during pregnancy: a review of evidence. Curr Drug Saf. 2015;10(2):170-9.
  20. Ranzco 
  21. Cohen A, Moschopoulos P, Stiehm RE, Koren G. Congenital varicella syndrome: the evidence for secondary prevention with varicella-zoster immune globulin. CMAJ. 2011;183(2):204–8.
  22. Jain, Sonia; Jakhar, Preeti. Herpes zoster ophthalmicus in pregnancy: A rare presentation. Journal of Medical Society 28(1):p 49-51, Jan–Apr 2014.
  23. Dworkin RH, Johnson RW, Breuer J et al Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44(Suppl 1): S1–26.
  24. Pupco A, Bozzo P, Koren G. Herpes zoster during pregnancy. Can Fam Physician. 2011 Oct;57(10):1133.
  25. Pontes, K.F.M.; Nardozza, L.M.M.; Peixoto et al. Cytomegalovirus and Pregnancy: A Narrative Review. J. Clin. Med. 2024, 13, 640.
  26. Cottreau, J.M.; Barr, V.O. A Review of Antiviral and Antifungal Use and Safety during Pregnancy. Pharmacother. J. Hum. Pharmacol. Drug Ther. 2016, 36, 668–678.
  27. Hu J, Zhang J, Li Y et al. A Combination of Intrastromal and Intracameral Injections of Amphotericin B in the Treatment of Severe Fungal Keratitis. J Ophthalmol; 2016:3436415.
  28. Bouten, M.; Elsheikha, H.M. Diagnosis and Management of Acanthamoeba Keratitis: A Continental Approach. Parasitologia 2022, 2, 167–197.
  29. Marciano-Cabral, F.; Puffenbarger, R.; Cabral, G.A. The Increasing Importance of Acanthamoeba Infections. J. Eukaryot Microbiol. 2000, 47, 29–36.
  30. Jones J, Lopez A, Wilson M. Congenital toxoplasmosis. Am Fam Physician. 2003 May 15;67(10):2131-8. PMID: 12776962.
  31. AAAO 
  32. AAAO 
  33. Chi, C.C.; Wang, S.-H.; Wojnarowska et al. Safety of Topical Corticosteroids in Pregnancy. Cochrane Database Syst. Rev. 2015, , CD007346.
  34. Chung, C.Y.; Kwok, A.K.H.; Chung, K.L. Use of Ophthalmic Medications during Pregnancy. Hong Kong Med. J. 2004, 10, 191–195.
  35. Concillado, M.; Lund-Andersen, H.; Mathiesen, E.R.; Larsen, M. Dexamethasone Intravitreal Implant for Diabetic Macular Edema During Pregnancy. Am. J. Ophthalmol. 2016, 165, 7–15.
  36. Wakefield, D.; El-Asrar, A.A.; McCluskey, P. Treatment of Severe Inflammatory Eye Disease in Patients of Reproductive Age and during Pregnancy. Ocul. Immunol. Inflamm. 2012, 20, 277–287.
  37. Russell MD et al. BSR Standards, Audit and Guidelines Working Group. Executive Summary: British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford). 2023 Apr 3;62(4):1370-1387.
  38. Rheumatology.org
  39. Antonucci, R.; Zaffanello, M.; Puxeddu et al Use of Non-Steroidal Anti-Inflammatory Drugs in Pregnancy: Impact on the Fetus and Newborn. Curr. Drug Metab. 2012, 13, 474–490.
  40. Mazzotta, P.; Loebstein, R.; Koren, G. Treating Allergic Rhinitis in Pregnancy. Drug Saf. 1999, 20, 361–375.
  41. Kar, S.; Krishnan, A.; Preetha, K.; Mohankar, A. A Review of Antihistamines Used during Pregnancy. J. Pharmacol. Pharmacother. 2012, 3, 105–108.
  42. Razeghinejad, M.R.M.; Masoumpour, M.M.; Eghbal et al. Glaucoma Surgery in Pregnancy: A Case Series and Literature Review. Iran. J. Med. Sci. 2016, 41, 437–445.
  43. Sharma, S.; Wuntakal, R.; Anand, A.; Sharma, T.K.; Downey, G. Pregnancy and the Eye. Obstet. Gynaecol. 2006, 8, 141–146.
  44. Razeghinejad, M.R. Glaucoma Medications in Pregnancy. Oman J. Ophthalmol. 2018, 11, 195–199.
  45. Salvetat, M.Let al.. Advancing Glaucoma Treatment During Pregnancy and Breastfeeding: Contemporary Management Strategies and Prospective Therapeutic Developments. Biomedicines 2024, 12, 2685.
  46. Eyewiki 
  47. Gotovac, M.; Kastelan, S.; Lukenda, A. Eye and Pregnancy. Coll. Antropol. 2013, 37 (Suppl. S1), 189–193.
  48. Ortega, D.; Viviand, X.; Lorec, A.M.; Gamerre, M. Excretion of Lidocaine and Bupivacaine in Breast Milk Following Epidural Anesthesia for Cesarean Delivery. Acta Anaesthesiol. Scand. 1999, 43, 394–397.
  49. Ferrara, N. Role of Vascular Endothelial Growth Factor in Regulation of Physiological Angiogenesis. Am. J. Physiol. Cell Physiol. 2001, 280, C1358–C1366.
  50. Galazios, G.; Papazoglou, D.; Tsikouras, P.; Kolios, G. Vascular Endothelial Growth Factor Gene Polymorphisms and Pregnancy. J. Matern. Fetal Neonatal Med. 2009, 22, 371–378.

Capitolul 19

  1. Sahutoglu C. „Anesthesia for ophthalmic surgery”. European Eye Research 2024;4(1):90-102.DOI:10.14744/eer.2023.44127.
  2. Crenguța Ioana Feraru. „Anestezia în oftalmologie”. Tratat de chirurgie, vol.2 Oftalmologie, coordonatori D.Chiseliță, C.P.Tătaru, Editura Academiei Române, 2024, pp.15-23.
  3. Guerrier G. „Pharmacologie des produits anesthesiques en ophtalmologie”. Medicaments et biotherapies en ophtalmologie, Elsevier Masson SAS, 2023, pp.379-384.
  4. Chandra Kumar (ed) et al. Ophthalmic Anaesthesia. Oxford Specialist Handbooks in Anaesthesia, 2012
  5. Leaming, David V. “Practice styles and preferences of ASCRS members--2003 survey.” Journal of cataract and refractive surgery vol. 30,4 (2004): 892-900. doi: 10.1016/j.jcrs.2004.02.064
  6. Taylor, A, and G McLeod. “Basic pharmacology of local anaesthetics.” BJA education vol. 20,2 (2020): 34-41. doi: 10.1016/j.bjae.2019.10.002
  7. Kumar, C M et al. “Local anaesthesia for ophthalmic surgery--new guidelines from the Royal College of Anaesthetists and the Royal College of Ophthalmologists.” Eye (London, England) vol. 26,6 (2012): 897-8. doi:10.1038/eye.2012.82
  8. Nazim-Lipski, G et al. “Mydrane intracameral injection site can be an alternative to mydriatic drops instillation in cataract surgery.” Journal of physiology and pharmacology: an official journal of the Polish Physiological Society vol. 71,2 (2020): 10.26402/jpp.2020.2.08. doi:10.26402/jpp.2020.2.08
  9. Eke, Tom. “Preoperative Preparation and Anesthesia for Trabeculectomy.” Journal of current glaucoma practice vol. 10,1 (2016): 21-35. doi:10.5005/jp-journals-10008-1198
  10. Fan, Hua et al. “A New Two-Step Anesthesia for 23- or 25-Gauge Vitrectomy Surgery: A Prospective, Randomized Clinical Trial.” Ophthalmic research vol. 64,1 (2021): 34-42. doi:10.1159/000508510
  11. Ing, Edsel B et al. “Local anesthesia and anxiolytic techniques for oculoplastic surgery.” Clinical ophthalmology (Auckland, N.Z.) vol. 13 153-160. 10 Jan. 2019, doi:10.2147/OPTH.S188790
  12. Mahan M, Flor R, Purt B “Local and Regional Anesthesia in Ophthalmology and Ocular Trauma”. 2023 May 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
  13. Dunville LM, Sood G, Kramer J. “Oculocardiac reflex. StatPearls “. StatPearls Publishing;Treasure Island (FL):Sep 19,2022.
  14. Rafailov, Leon et al. “Comparison of Lidocaine Gel-Assisted Transconjunctival and Transcutaneous Local Anesthesia for Outpatient Eyelid Surgery.” Ophthalmic plastic and reconstructive surgery vol. 31,6 (2015): 470-3. doi:10.1097/IOP.0000000000000391

Capitolul 20

  1. Francine Behar-Cohen, Francois Chast. „Medicaments et Biotherapies en Ophtalmologie, Ed. Elsevier Masson, 2023
  2. Satish S Modi, James A Davison,Tom Walters. „Safety, efficacy, and intraoperative characteristics of DisCoVisc and Healon ophthalmic viscosurgical devices for cataract surgery” Clinical Ophtalmology, september 2011:5, 1381 – 1389
  3. Jean-Paul Renard, Eric Sellem. „Glaucome primitif a angle ouvert”, Ed. Elsevier Masson, 2009
  4. „Acid hialuronic”, PubChem. . Fraser JR, Laurent TC, Laurent UB (1997).
  5. „Hyaluronan: its nature, distribution, functions and-turnover”. J.Intern.Med. 242 (1):27/33. doi:10.1046/j.1365-2796.1997. 00170.x.
  6. "FD&C Blue 1 (Brilliant Blue)". International Association of Color Manufacturers. Archived from the original on 2019-05-06. Retrieved 2019-05-06.
  7. FD&C Blue No. 1: Brilliant Blue FCF Food Dye". culinarylore.com. 2015-08-04. Retrieved 2019-06-03.
  8. Irinel Popescu, Vlad Alexandru Ciurea. „Tratat de chirurgie”, volumul 2 „Oftalmologie”, coordonatori Dorin Chiseliţă, Călin Petru Tătaru. Editura Academiei Române, 2024
  9. Georges Caputo, Florence Metge-Galatoire, Carl Arndt, John Conrath. „Decollements de retine”, Ed. Elsevier Masson, 2011
  10. Myron Yanoff, Jay S. Duker. „Tratat de Oftalmologie”, Ediţia a cincea, în limba română, Coordonator Călin Petru Tătaru. Editura Prior, 2020

Capitolul 21I

  1. O'Farrill N, Abi Karam M, Villegas VM, et al. „New Approaches to Overcoming Antimicrobial Resistance in Endophthalmitis.” Pharmaceuticals (Basel). 2024 Mar 1;17(3):321.
  2. Ordin al Ministerului Sănătății nr. 63 din 10 ianuarie 2024 privind reglementarea metodologiei de monitorizare a prescrierii și eliberării la nivel național a medicamentelor din categoria antibiotice și antifungice de uz sistemic, publicat în Monitorul Oficial nr. 41 din 17 ianuarie 2024.
  3. Cabrera-Aguas M, Chidi-Egboka N, Kandel H, Watson SL. „Antimicrobial resistance in ocular infection: A review.” Clin Exp Ophthalmol. 2024 Apr;52(3):258-275.
  4. Behar-Cohen, Francine și Chast, François, ed. Médicaments et biothérapies en ophthalmologie. Ed. Elsevier-Masson, 2023, pp. 211-230 (cap. Antibiotyques et antifongiques).
  5. Preferred Practice Pattern: Conjunctivitis, American Academy of Ophthalmology, 2023.
  6. Mannis M, Holland E, ed. Cornea. Editia a 5-a, Elsevier, 2021 cap 40 Ophthalmia neonatorum.
  7. Oikonomakou MZ, Makri OE, Panoutsou E, et al. „Bacteriology and Antimicrobial Susceptibility Patterns of Childhood Acute Bacterial Conjunctivitis in Western Greece.” Med Hypothesis Discov Innov Ophthalmol. 2019 Winter;8(4):266-271.
  8. Chan VF, Yong AC, Azuara-Blanco A, Gordon I, et al. „A Systematic Review of Clinical Practice Guidelines for Infectious and Non-infectious Conjunctivitis.” Ophthalmic Epidemiol. 2022 Oct;29(5):473-482.
  9. Preferred Practice Pattern: Bacterial Keratitis, American Academy of Ophthalmology, 2023.
  10. Barry P, Cordoves L, Gardner S ESCRS Guidelines for Prevention and Treatment of Endophthalmitis Following Cataract Surgery, publicat de ESCRS, 2013.
  11. Grzybowski A, Brona P, Zeman L, Stewart MW. Commonly used intracameral antibiotics for endophthalmitis prophylaxis: A literature review. Surv Ophthalmol. 2021 Jan-Feb;66(1):98-108.
  12.  Sadda S, Sarraf D, Bayley Freund K et al., ed. Ryan’s Retina. ediția a 7-a. Elsevier, 2023 – cap.122 Endophthalmitis.
  13. Danielescu C, Anton N, Stanca HT, Munteanu M. „Endogenous Endophthalmitis: A Review of Case Series Published between 2011 and 2020.” J Ophthalmol. 2020 Oct 23; 2020:8869590.

Capitolul 21I

  1. Francine Behar-Cohen, Francois Chast. „Medicaments et Biotherapies en Ophtalmologie, Ed. Elsevier Masson, 2023
  2. Satish S Modi, James A Davison,Tom Walters. „Safety, efficacy, and intraoperative characteristics of DisCoVisc and Healon ophthalmic viscosurgical devices for cataract surgery” Clinical Ophtalmology, september 2011:5, 1381 – 1389
  3. Jean-Paul Renard, Eric Sellem. „Glaucome primitif a angle ouvert”, Ed. Elsevier Masson, 2009
  4. „Acid hialuronic”, PubChem. . Fraser JR, Laurent TC, Laurent UB (1997).
  5. „Hyaluronan: its nature, distribution, functions and-turnover”. J.Intern.Med. 242 (1):27/33. doi:10.1046/j.1365-2796.1997. 00170.x.
  6. "FD&C Blue 1 (Brilliant Blue)". International Association of Color Manufacturers. Archived from the original on 2019-05-06. Retrieved 2019-05-06.
  7. FD&C Blue No. 1: Brilliant Blue FCF Food Dye". culinarylore.com. 2015-08-04. Retrieved 2019-06-03.
  8. Irinel Popescu, Vlad Alexandru Ciurea. „Tratat de chirurgie”, volumul 2 „Oftalmologie”, coordonatori Dorin Chiseliţă, Călin Petru Tătaru. Editura Academiei Române, 2024
  9. Georges Caputo, Florence Metge-Galatoire, Carl Arndt, John Conrath. „Decollements de retine”, Ed. Elsevier Masson, 2011
  10. Myron Yanoff, Jay S. Duker. „Tratat de Oftalmologie”, Ediţia a cincea, în limba română, Coordonator Călin Petru Tătaru. Editura Prior, 2020

Capitolul 21II

  1. Speaker, M. G., și J. A. Menikoff. „Prophylaxis of endophthalmitis with topical povidone-iodine.” Ophthalmology, vol. 98, 1991, pp. 1769–1775. doi: 10.1016/S0161-6420(91)32052-9.
  2. Borgia, A., et al. „Prophylaxis of Ocular Infection in the Setting of Intraocular Surgery: Implications for Clinical Practice and Risk Management.” Ophthalmology and Therapy, vol. 12, no. 2, 2023, pp. 721–734. doi: 10.1007/s40123-023-00661-9.
  3. Barry, P., L. Cordovés, și S. Gardner. ESCRS Guidelines for Prevention and Treatment of Endophthalmitis Following Cataract Surgery.
  4. Miño de Kaspar, H., et al. „A prospective randomized study to determine the efficacy of preoperative topical levofloxacin in reducing conjunctival bacterial flora.” Am. Journal of Ophthalmology, vol. 145, 2008, pp. 136–142.e2.

Capitolul 21III

  1. Brandsdorfer, Ari, Sejal H. Patel, and Roy S. Chuck. “The role of perioperative nonsteroidal anti-inflammatory drugs uses in cataract surgery.” Current Opinion in Ophthalmology, vol. 30, no. 1, Jan. 2019, pp. 44–49. DOI: 10.1097/ICU.0000000000000541.
  2. Olson, Randall J., Reena Braga-Mele, Stephanie H. Chen, et al. “Cataract in the adult eye preferred practice pattern®.” Ophthalmology, vol. 124, 2017, pp. P1–P119.
  3. Dietlein, T. S., C. Erb, and E. Hoffmann. “Perioperative antientzündliche Therapie im Rahmen der Glaukomchirurgie [Perioperative Anti-inflammatory Treatment in Glaucoma Surgery].” Klinische Monatsblätter für Augenheilkunde, vol. 236, no. 5, May 2019, pp. 647–652.
  4. Ahmadzadeh, A., L. Kessel, B. S. Schmidt, M. Kolko, and D. Bach-Holm. “Steroids and/or Non-Steroidal Anti-Inflammatory Drugs as Postoperative Treatment after Trabeculectomy—12-Month Results of a Randomized Controlled Trial.” Journal of Clinical Medicine, vol. 13, 2024, p. 887.
  5. Romano, V., M. Angi, F. Scotti, R. del Grosso, D. Romano, F. Semeraro, P. Vinciguerra, C. Costagliola, and M. R. Romano. “Inflammation and macular oedema after pars plana vitrectomy.” Mediators of Inflammation, 2013, pp. 1–8. DOI: 10.1155/2013/971758.
  6. Moshfeghi, Debra M., Amir A. Moshfeghi, and Paul T. Finger. “Enucleation.” Survey of Ophthalmology, vol. 44, no. 4, 2000, pp. 277–301. DOI: 10.1016/s0039-6257(99)00112-5.

Capitolul 21IV

  1. Lesin, M., J. Domazet Bugarin, și L. Puljak. „Factors associated with postoperative pain and analgesic consumption in ophthalmic surgery: a systematic review.” Survey of Ophthalmology, vol. 60, no. 3, 2015, pp. 196-203. doi: 10.1016/j.survophthal.2014.10.003.
  2. Assam, J. H., A. Bernhisel, și A. Lin. „Intraoperative and postoperative pain in cataract surgery.” Survey of Ophthalmology, vol. 63, no. 1, 2018, pp. 75-85.
  3. Ye, H., et al. „Risk factors associated with postoperative pain and discomfort in oculoplastic surgery with general anesthesia: a prospective study.” Journal of Pain Research, vol. 11, 2018, pp. 407-415. doi: 10.2147/JPR.S156104.
  4. Ye, H., et al. „Intraoperative administration of intravenous flurbiprofen axetil with nalbuphine reduces postoperative pain after orbital decompression: a single-center, prospective randomized controlled trial.” Journal of Pain Research, vol. 12, 2019, pp. 659-665. doi: 10.2147/JPR.S187020.

Capitolul 22

Carte

1. NR Biswas, Vinei Gupta, Ashok Dubey-Ocular therapeutics 3rd edition, CBS Publishers and Distributors Pvt.Ltd, 2019.

2. RL Sharma, Kaplana Sharma, Kamlesh Sharma-Texrtbook of ophthalmic Pharmacology and therapies, IP Innovative Publications Pvt.Ltd., 2020.

3. Dorin Chiseliță (Ed.)-Ghid practic de urgențe în oftalmologie, Editura Cermi, 2018. Capitol de carte1. Francoise. Chast "Medicaments antalgiues"" în Medicaments et biotherapies enophtalmologie editat de Francine Behar-Cohen, Francois Chast, Ed. Elsevier Masson SAS, 2023.pp 311-326.

2. Dorin Chiseliță Durerea oculară și perioculară" în Tratat de algeziologie,sub redacția Ostin C.Mungiu,Editura Polirom, 2002, pp 887-903.


Articole de jurnal
1. Razavi, Alexander C et al. “Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a).” American journal of preventive cardiology vol. 18 100674. 27 Apr. 2024, doi: 10.1016/ j.ajpc. 2024.100674.

2. Chaiamnuay, Sumapa et al. “Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.” American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists vol. 63,19 (2006): 1837-51. doi:10.2146/ajhp0505193.

3. Kim, Stephen J et al. “Nonsteroidal anti-inflammatory drugs in ophthalmology.” Survey of ophthalmology vol. 55,2 (2010): 108-33. doi: 10.1016/j.survophthal.2009.07.005.

4. Harirforoosh, Sam et al. “Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications.” Journal of pharmacy & pharmaceutical sciences: a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques vol. 16,5 (2013): 821-47. doi:10.18433/j3vw2f.

5. Graham, Garry G, and Kieran F Scott. “Mechanism of action of paracetamol.” American journal of therapeutics vol. 12,1 (2005): 46-55. doi:10.1097/00045391-200501000-00008.

6. Pereira, Vinicius Bp et al. “Opioids for Ocular Pain - A Narrative Review.” Pain physician vol. 20,5 (2017): 429-436.

7. Goldstein, Nathan E, and R Sean Morrison. “Treatment of pain in older patients.” Critical reviews in oncology/hematology vol. 54,2 (2005): 157-64. doi: 10.1016/j.critrevonc.2005.01.001.

8. Koren, G et al. “Drugs in pregnancy.” The New England journal of medicine vol. 338,16 (1998): 1128-37. doi:10.1056/NEJM199804163381607.

9. Miller, James Rc, and Daren Hanumunthadu. “Inflammatory eye disease: An overview of clinical presentation and management.” Clinical medicine (London, England) vol. 22,2 (2022): 100-103. doi:10.7861/clinmed.2022-0046.

10. Dick, Andrew D et al. “Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals of Care for UveitiS (FOCUS) Initiative.” Ophthalmology vol. 125,5 (2018): 757-773. doi: 10.1016/j.ophtha.2017.11.017.

11. Fiorelli, Vanessa M B et al. “Nonsteroidal anti-inflammatory therapy and recurrent acute anterior uveitis.” Ocular immunology and inflammation vol. 18,2 (2010): 116-20. doi:10.3109/09273941003587558.

12. Leonardi, Andrea et al. “Coexistence of neuropathic corneal pain, corneal nerve abnormalities, depression, and low quality of life.” Eye (London, England) vol. 38,3 (2024): 499-506. doi:10.1038/s41433-023-02710-w.

13. Finnerup, Nanna B et al. “Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.” The Lancet. Neurology vol. 14,2 (2015): 162-73. doi:10.1016/S1474-4422(14)70251-0.

14. Aggarwal, Shruti et al. “Efficacy of autologous serum tears for treatment of neuropathic corneal pain.” The ocular surface vol. 17,3 (2019): 532-539. doi: 10.1016/j.jtos.2019.01.009.

García-López, Celia et al. “Opioids and Ocular Surface Pathology: A Literature Review of New Treatments Horizons.” Journal of clinical medicine vol. 11,5 1424. 4 Mar. 2022, doi:10.3390/jcm11051424.

16. Ozmen, M Cuneyt et al. “Efficacy and tolerability of nortriptyline in the management of neuropathic corneal pain.” The ocular surface vol. 18,4 (2020): 814-820. doi: 10.1016/j.jtos.2020.08.006.

17. Patel, Sneh et al. “Neuropathic ocular surface pain: Emerging drug targets and therapeutic implications.” Expert opinion on therapeutic targets vol. 26,8 (2022): 681-695. doi:10.1080/14728222.2022.2122438.

18. Le, Damien Tuan-Man et al. “Evaluation of ocular neuropathic pain.” The ocular surface vol. 30 (2023): 213-235. doi: 10.1016/j.jtos.2023.09.009.

© 2025+ Toate drepturile rezervate